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ABSTRACT

MicroRNAs (miRNA, miR) are traditionally thought of as negative regulators of posttranscriptional gene expression. However, recent work shows that rarely, some miRNAs actually
increase transcription or translation of their targets. MiR-152-3p is one such unique miRNA. We
demonstrate miR-152-3p enhances protein expression of SET domain bifurcate 1 (SETDB1), a
histone methyltransferase responsible for trimethylation of histone 3 lysine 9 (H3K9me3).
Heterochromatin protein 1 (HP1) binds to H3K9me3 to assist in the formation and maintenance
of transcriptionally inactive regions of DNA called constitutive heterochromatin, which in turn is
associated with gene silencing. We conclude regulation of SETDB1 by miR-152-3p has
functional consequences on H3K9me3 levels. Therefore, positive regulation of SETDB1 by
miR-152-3p is the first known example of a miRNA which promotes the formation of
constitutive heterochromatin by serving as an indirect epigenetic modifier. The miRanda
database algorithmically predicts three target recognition sequences (TRS) in the 3’UTR of
SETDB1. We inserted the SETDB1 3’UTR into a luciferase reporter vector and deleted each
TRS to demonstrate the necessity of these TRS for full luciferase expression. We found that at
least one of the TRS is required for full luciferase expression. We are the first to demonstrate a
miRNA which positively regulates protein synthesis does so by targeting the 3’UTR, rather than
the 5’UTR. In order to study the effects of miR-152-3p on SETDB1 mRNA and protein, we
modulated levels of the miRNA with mimic or inhibitor (anti-miR). The mimic replicates the
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functioning of endogenous miR-152-3p and the anti-miR prevents endogenous miR from binding
to its targets. Using these tools, we found miR-152-3p mimic treatment increased SETDB1
protein levels, decreased H3K9me2 levels, and increased H3K9me3 levels. Conversely,
inhibition of miR-152-3p decreased SETDB1 protein levels and increased H3K9me2 levels. No
correlation was observed between miR-152-3p and SETDB1 mRNA, indicating the miRNA
likely acts on translation machinery. Through this work, we advance our knowledge and
understanding of miRNA roles in protein and epigenetic regulation. Our finding that miR-152-3p
indirectly promotes the epigenetic modification associated with heterochromatin formation and
gene silencing provides a novel perspective from which to approach research in the field of
epigenetics.
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CHAPTER 1
INTRODUCTION AND BACKGROUND

Introduction

Rationale
According to an algorithm developed by MicroRNA.org (miRanda), the miRNA miR152-3p targets the histone lysine methyltransferase SETDB1 (su(var) 3-9 enhancer of zeste
trithorax domain bifurcate 1) at the 3’UTR1. The algorithm makes this prediction by applying
rules of miRNA-mRNA binding to the known sequences of miRNAs and mRNA targets. These
rules are devised from patterns in experimentally determined and accepted miRNA-mRNA
binding pairs. However, the binding of miR-152-3p to the SETDB1 3’UTR has not been
experimentally confirmed. The only experimental evidence that miR-152-3p targets SETDB1 is
from a CLASH (crosslinking, ligation, and sequencing of hybrids) binding assay, but CLASH
showed that miR-152-3p binds to the coding sequence (CDS) instead of the miRanda predicted
3’UTR of SETDB12. A potential reason for this discrepancy is that CLASH can include data on
transient interactions, since the first step of the procedure is to crosslink. Our work aimed to
confirm the miRanda predicted target recognition sites (TRS) and provided strong evidence that
miR-152-3p binds to the 3’UTR.
Because miR-152-3p potentially targets SETDB1, we hypothesized that miR-152-3p
regulates SETDB1, but there is no evidence in the literature to support this. Furthermore,
1

whether miR-152-3p promotes or represses SETDB1 expression is unknown. MiRNAs are often
described as acting only in a repressive manner1. Yet, there are rare instances of miRNAs
upregulating transcript or protein expression of their targets3-5. Therefore, it cannot be assumed
that miRNAs exclusively destabilize mRNA or repress translation. For these reasons, our work
aimed to determine if miR-152-3p affects SETDB1 at the mRNA or protein levels and to
determine if miR-152-3p promotes or represses SETDB1 expression.
SETDB1 is a histone methyl transferase responsible for adding a methyl group on to
dimethylated histone H3 lysine 9 (H3K9me2) residues in euchromatin, forming trimethyl histone
H3 lysine 9 (H3K9me3)6. H3K9me3 initiates the binding of HP1, a structural component
responsible for the maintenance and renewal of heterochromatin7-9. Therefore, if miR-152-3p
targets and regulates SETDB1, it is predicted that miR-152-3p impacts the epigenetic
modifications of H3K9 and, by extension, chromatin structure via HP1 recruitment. To address
this prediction, our work aimed to demonstrate whether manipulation of miR-152-3p
significantly affects H3K9me2/3 levels and HP1 localization.

Biological and Medical Significance
Our work has two primary sources of biological and medical significance. First, we
provide biological information on miR-152-3p. Without our research, it was unknown whether
miR-152-3p targeted the 3’UTR of SETDB1 in vivo. We were first to perform mutagenesis at the
3’UTR of SETDB1 and confirm any miRNA activity at the 3’UTR of SETDB1. With the present
CLASH data, it is not known if miR-152-3p binding to SETDB1 represents a transient or stable,
regulatory, interaction. Furthermore, the directionality (promoting or repressing) and level
2

(mRNA or protein) of SETDB1 regulation are unidentified in the literature. We concluded miR152-3p positively regulates SETDB1 protein synthesis, and in doing so, contributed to the
present knowledge.
Second, we provided the crucial foundation upon which disease-relevant work can be
based. In addition to pioneering experiment-based research on miR-152-3p binding to the 3’UTR
of SETDB1, we were also the first to demonstrate a corresponding impact on histone
methylation status. Histone methylation is not presented in the literature as being susceptible to
control by a miRNA. In looking at the indirect consequences of miR-152-3p regulation of
SETDB1 on H3K9me2/3, a greater understanding of miRNA regulation of histone methylation is
achieved.
With this novel understanding, new approaches in disease research can be taken since
abnormalities in histone methylation status are heavily implicated in diseases such as cancer and
Huntington’s disease (HD). There is evidence that decreasing expression of SETDB1 improves
disease outcome and increasing levels of miR-152 reduces cancer progression. One group found
SETDB1 and H3K9me3 levels are coordinated in HD. When SETDB1 is chemically downregulated, hypermethylation at H3K9 is reduced, and survival is extended by over 40% in HD
model mice10. According to Dang, et. al., miR-152 is down-regulated in hepatocellular
carcinoma (HCC), and this under expression of miR-152 is promotes hepatocarcinogenesis by
dysregulating cell proliferation, cell motility, and apoptosis11. Interestingly, Wong, et. al.
determined that SETDB1 expression is elevated in hepatocellular carcinoma12. Through our
work, a disease pathway can be constructed to help put existing research into a new context.
With further studies, our work may also contribute towards elucidating what part of the pathway
is aberrant in diseases such as HD and HCC.
3

Background

MicroRNAs and miR-152-3p
MicroRNAs (miRNA, miR) are a class of small, single-stranded, non-coding RNAs that
primarily post-transcriptionally regulate gene expression. MiRNAs can target regions of mRNA,
resulting in gene silencing. This is accomplished through mRNA cleavage or translational
repression1. Rarely, miRNAs may increase transcription or translation of their targets. In the case
of miR-324-3p, RelA is transcriptionally activated upon promoter-miRNA binding in an Ago2dependednt manner5. In regards to translation, miR-10a and miR-122 have both been found to
stimulate translation of targets. MiR-10a enhances translation by binding to the 5’UTR of target
ribosomal mRNA3. MiR-122 acts by increasing the association of ribosomes with hepatitis C
virus (HCV) RNA during the initiation of translation, thereby increasing translation of HCV4, 13.
MiR-152-3p is one miRNA that is thought to target the coding region of SETDB12. The
miRanda database further indicates that miR-152-3p may target the 3’UTR of SETDB114.
It is believed that most miRNA genes come from regions of the genome far from
previously annotated genes. This may mean that those distant miRNA genes are derived from
their own independent transcription units, according to a primary literature review on miRNA
biogenesis by Bartel. However, similar to small nucleolar RNAs (snoRNAs), approximately one
quarter of miRNA genes are processed from the introns of pre-mRNAs1. These miRNAs are
called intronic miRNAs and are processed from unspliced intronic regions prior to splicing
catalysis15. Since intronic miRNAs lack their own promoters, coordinated expression of miRNAs
and proteins can be seen1. MiR-152 is an example of an intronic miRNA gene. It is 109 base
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pairs in length and located between the first and second exons of the COPZ2 gene at locus
17q21.3216.
Canonical miRNA biogenesis begins with Drosha, an RNase III endonuclease, cleaving
the primary miRNA (pri-miRNA) in the nucleus. This releases an approximately 60-70
nucleotide stem-loop intermediate, called the precursor miRNA (pre-miRNA). Exportin 5 and
ran-GTP then transport the pre-miRNA out of the nucleus. In the cytosol, Dicer, which is also an
RNase III endonuclease, recognizes and cuts the double-stranded portion of the pre-miRNA.
This forms a very short-lived miRNA-miRNA duplex. The mature miRNA forms a complex
with RNA-induced silencing complex (RISC) based on thermodynamic instability. The weaker
stand is degraded; however, sometimes both miRNAs are equally viable and can complex with
RISC1. The miRNA-containing RISC (miRISC) in humans was first discovered under the name
miRNA ribonucleoprotein complex (miRNP)17 and the two terms are generally accepted as
synonymous. The miRISC includes helicase proteins and eIF2C2, a human Argonaute protein
homolog17. Interestingly, Ago2 can process pre-miRNAs into mature miRNAs independently of
Dicer18. This capability represents one of the many bourgeoning non-canonical pathways for
miRNA biogenesis.
MiRNAs are involved in the development and differentiation of various tissues. MiR152-3p has been implicated in hepatocyte differentiation. In a 2011 study by Kim, et.al., miR152 was found to be among the top ten miRNAs which increases in expression during the
transition from definitive endoderm to hepatocyte cell19. Our own experimental results from the
differentiation of human induced pluripotent stem cells to hepatocyte-like cells (HLC) supported
these findings. We also found miR-152 expression increased during stage 4, HLC production.
This result is discussed more fully in Chapter 6, Future Directions Part II. Examples of miRNAs
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in development include: miR-27b, which has been implicated with myogenesis20, and miRs-124,
-221, and -222, which are involved in neurogenesis21.
MiRNAs are also heavily studied as biomarkers for diseases. For example, miR-1 is
under investigation as a marker for cardiac disease and increased miR-122 is associated with
liver cancer1, 4. Currently, there are few studies focused exclusively on miR-152. Much of the
information present comes from miRNA screens done in search of miRs that are highly
expressed in disease tissues. Data from such miRNA screens implicates miR-152 in hepatic
glycogenesis regulation22 and points to miR-152 as a biomarker for the early detections of breast
cancer, colorectal carcinoma, and lung cancer23. In addition to this disease-specific data on miR152 expression, the remainder of existing research on miR-152 examines its mRNA targets. A
list of experimentally validated targets for the 3 prime homo sapien miR-152 (hsa-miR-152-3p)
is included in Appendix II: Supplementary Data24.

Histone Modifications
Accurate epigenetic maintenance and inheritance is important for the proper development
and functioning of cells. Broadly, there are two type of chromatin: euchromatin and
heterochromatin. Euchromatin results from the loosening of DNA around histones so
transcription can occur. Heterochromatin exists when DNA is tightly wound around histones
such that it cannot be accessed by transcription machinery. There are two types of
heterochromatin: constitutive and facultative. As implied by the nomenclature, constitutive
heterochromatin is permanent while facultative tends to be temporary. The transitions among
these types of chromatin are due to modifications made to histones.

6

Histones can undergo dynamic post-translational modifications such as acetylation,
phosphorylation, methylation, and ubiquitination. Many of these modifications alter the
interaction of DNA with histones and can result in conformational changes from heterochromatin
to euchromatin, or vice versa. This change in chromatin organization ultimately influences gene
expression by affecting access to genes for transcription factors, DNA repair enzymes, DNA
replication machinery, or enzymes involved in recombination. Proper epigenetic regulation is
critical for normal cellular function and development. Research has shown that some epigenetic
changes can even have transgenerational consequences25, 26. Thus, the study of epigenetics is
important in understanding cellular processes and disease.
The Brno nomenclature system is employed when histone modifications are discussed in
the literature. This system, first published by Turner in 2005, was devised following a meeting of
the Epigenome Network of Excellence in Brno, Czech Republic, from which it gains its
namesake. The Brno nomenclature system condenses a description of histone modifications into
an easily readable and understandable abbreviation. The first letter, H, denotes histone, and the
first number following indicates which histone is being described. For example, H3 means
Histone 3. The second letter is the single-letter amino acid code designation and is paired with a
number to indicate which amino acid residue gains modification(s). For example, K9 means
lysine number 9. Finally, a short letter abbreviation is used to describe the modification(s).
Accepted abbreviations include “me” for “methylation”, “ac” for “acetylation”, and “ph” for
“phosphorylation”. The last number shown, if any, denotes how many times that modification is
present at that particular residue. For example, me2 means dimethylated. The letter “a” or “s”
might be written at the end of the Brno name to indicate either an “asymmetrical” or
“symmetrical” addition, respectively27.

7

Histone Methylation
Histone methylation can occur on arginine (R) or lysine (K) residues. One key difference
between these types of methylation is the stability of these modifications; lysine methylation is
more stable than that of arginine28. This is due to the presence of a destabilizing imino- group
seen in the guanidino methyl28. When R methylation occurs, it takes place on the η1 nitrogen of
the amino-specific residue, creating either a monomethyl-, symmetric dimethyl-, or an
asymmetric dimethylarginine29. Conversely, K methylation takes place on the Nε of the aminospecific residue and K methylation has a lower turnover than R methylation28.
In regards to function, methylation of arginine regulates protein-protein interactions.
More specifically, R methylation facilitates the interaction of guanine and arginine-rich and
proline-, glycine-, methionine-, arginine-rich motifs with proteins containing Tudor domains29.
Tudor domain protein binding can be favorable or negative, depending on the quantity and
conformation of R methylation29. By contrast, lysine methylation results in changes in gene
expression. Examples of events which proceed from lysine methylation include heterochromatin
formation and X-chromosome inactivation. These changes can be either silencing or activating,
depending on the quantity and lysine position being methylated. For example, methylation of H3
at K4, K36, or K79 is usually associated with gene activation, while methylation of H3 at K9 or
K27 and of H4 at K20 generally results in gene silencing30. In addition to these positions, lysine
residues on H1 can also be methylated at various positions28. Lysine methylation can occur up to
three times, resulting in mono-, di-, or trimethylated versions of each lysine residue.
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Lysine Methyltransferases (KMTs) and Demethylases (KDMs)
Lysine methylation is accomplished by a class of enzymes called lysine methyl
transferases (KMTs). KMTs transfer up to three methyl groups from a single S-adenosyl-Lmethionine (SAM or AdoMet) at a time31. SAM is synthesized from methionine using AdoMet
synthetase32. Upon transfer of SAM’s methyl group to lysine by methylase, Sadenosylhomocysteine (AdoHyc) is formed32. AdoHyc is hydrolyzed to adenosine and
homocysteine, the latter of which can be synthesized to methionine and used for further SAM
synthesis in the SAM cycle32.
The discovery of a lysine demethylase (KDM) is relatively recent, with the earliest
published findings in 200433. In the Cell article, Shi, et. al. identified lysine-specific demethylase
1 (LSD1), an H3K4 demethylase33. Since then, additional KDMs have been identified and their
functions continue to be characterized. One such example is KDM2A, which was initially
identified in 2005 as an H3K36 demethylase34. In 2016, research was published demonstrating
KDM2A binds to heterochromatin protein 1 alpha (HP1α)35 Given the role of HP1α in the
maintenance of heterochromatin formation via increased KMT recruitment8, it would be
expected that KDM2A-HP1α binding may result in increased H3K9 methylation35. This work
provides an example in which a demethylase for one H3 lysine residue, K36, may be responsible
for stimulating methylation of another H3 lysine residue, K9. This area of research is fairly new
and merits continued study in order to fully understand the complex roles of KDMs.
Structurally, all KMTs possess a highly conserved Su(var)3-9, Enhancer of Zeste,
Trithorax (SET) domain in which the enzymatic activity occurs31. The only known exception to
this structure is KMT4, also called DOT1L, which lacks a SET domain31. The KMTs are divided
into families which are sequentially numbered KMT1 through KMT830. The KMT1 family

9

includes H3K9me2 KMTs: KMT1C (G9a) and KMT1D (GLP)30. The KMT1 family also
consists of H3K9me3 KMTs: KMT1A (SUV39H1), KMT1B (SUV39H2), KMT1E (SETDB1),
and KMT1F (SETDB2)30. KMTs are of great importance due to their roles in gene expression.
KMT1E, commonly referred to as SETDB1, is of particular interest.

Su(var) 3-9 Enhancer of Zeste, Trithorax Domain Bifurcate 1 (SETDB1)
The diverse functions of SETDB1 are part of what make this KMT particularly
fascinating. SETDB1 trimethylates histone H3 at lysine 9 resides (H3K9me3) in euchromatin
regions6. It has also been found to mono- and dimethylate H3K9 during translation36. Research
also shows that SETDB1 monomethylates at H3K9 when H3K9 is trimethylated by Suv39 at
pericentric heterochromatin37. Due to these distinctive functions bearing different consequences,
the regulation of SETDB1 is especially intriguing.
Much of what is known about the structure and function of SETDB1 originates from a
groundbreaking study by Schultz, et. al. from 2002. They found the C-terminal region of
SETDB1 consists of three domains: pre-SET, SET, and post-SET. They characterized the SET
domain as being bifurcate. This means the SET domain is split in parts (therefore creating preSET and post-SET domains) due to the presence of a 347 amino acid insert (Figure 1.1). This
amino acid insert is conserved across species, from human to C. elegans and D. melanogaster,
and does not affect the catalytic activity of SETDB1. SETDB1 is described as having two other
key features, a KAP-1 interacting domain (KID) and a methyl-binding domain (MBD) (Figure
1.1). The KID facilitates proper KMT activity. However, KAP-1 binding is not required for
HMT activity. KAP-1 targets SETDB1 to gene promoters transcriptionally silenced by a KRAB
repressor protein. The MBD, more specifically, is a CpG-DNA methyl binding domain of the
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MeCP2 family38. While SETDB1 contains this MBD, it is unknown if it actually binds
methylated DNA39. According to Ensembl, the SETDB1 gene is located in chromosome 1 at
position 150,926,263-150,964,74440.

Figure 1.1 The domain organization of SETDB1 determined and depicted by
Schultz, et. al38. SETDB1 has an amine KID. SETD1 also contains a MBD, and
C-terminus SET domain. The SET domain is bifurcate with a conserved amino
acid insert that serves no known purpose.

SETDB1 can be regulated exogenously with inhibitors of SAM such as DZNep41. DZNep
inhibits AdoHyc hydrolase41, thus disrupting the SAM cycle. Endogenously, post-translational
modification of SETDB1, such as ubiquitination, deamination, and phosphorylation, regulates its
HMT activity42. For example, it has been shown that lysine 867 ubiquitination is necessary for
full H3K9 methytransferase activity42. While direct ubiquitination of SETDB1 enhances its
HMT activity, ubiquitination which targets the protein for degradation could downregulate HMT
activity. Another manner in which SETDB1 is regulated within the cell is by direct targeting
from miRNAs. In humans, miRanda predicts that miR-296-3p, -324-3p, 152-3p, 92a-3p, and 1260b target SETDB114. CLASH confirms binding of these miRNAs to SETDB1, though not
necessarily at the same sites predicted by miRanda2.
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SETDB1 is of particular interest due to its role in diseases and epigenetics. SETDB1 is
upregulated in Huntington’s Disease and the increased SETDB1 is linked to increased
H3K9me3. When SETDB1 is knocked down in HD mice, H3K9me3 levels are also reduced and
a decrease in neuronal degradation is observed10. Upregulation of SETDB1 is also implicated in
the metastasis of hepatocellular carcinoma (HCC). Upon knock-down of SETDB1, HCC
proliferation and cancer cell migration are reduced12. Thus, modulation of SETDB1 with a
miRNA has disease implications and potential therapeutic applications.

Histone 3 Lysine 9 (H3K9) Methylation
KMT1C (G9a/EHMT2) is responsible for monomethylation of H3K943 (Figure 1.2).
Within eukaryotes, the role of H3K9me1 as either gene silencing or activating is split. For
example, H3K9me1 serves as a mark of gene silencing in Chlamydomonas reinhardtii, a type of
green algae. However, H3K9me1 is associated with gene activation in humans. One study of
over 12,000 genes found that H3K9me1 was enriched at active promoters surrounding the
transcription start site44. Another study indicates that H3K9me1 is localized to euchromatin
regions of silenced genes45. Furthermore, there is evidence that H3K9me1 acts cooperatively
with H4K20me1 to designate distinct regions of silent chromatin46.
Dimethylation at histone H3 lysine 9 (H3K9me2) arises from KMT1C (G9a/EHMT2)
and KMT1D (GLP/EHMT1)30 (Figure 1.2) and is enriched in silent genes44. H3K9me2 is
characteristic of X chromosome inactivation47. H3K9me2, in combination with H3K27me3,
recruits a chromatin-associated protein called Cdyl. Cdyl serves as a binding partner for G9a,
which then propagates H3K9me2 in X chromosome inactivation48. H3K9me2 is also localized to
12

euchromatin regions of silenced genes45. H3K9me1/2 is reversed by KDM families 1, 3, and 730
(Figure 1.2).
Trimethylation of H3K9 (H3K9me3) is accomplished by five different enzymes,
including KMT1E (SETDB1) (Figure 1.2)30 and is enriched in heterochromatin45. SETDB1 is
specifically responsible for converting H3K9me2 to H3K9me3. H3K9me3 levels are higher than
H3K9me1 in a 10kb region of the transcription start site surrounding silent genes44. Previous
work supports the assertion that H3K9me3 is associated with heterochromatin formation and
gene silencing by binding to heterochromatin protein 1 (HP1), which assists in the selfmaintenance of heterochromatin49. H3K9me2/3 is only reversed by the KDM4 family30.
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Figure 1.2 Summary of H3K9 methylation and demethylation enzymes.
H3K9 mono- and dimethylation is accomplished only by G9a. H3K9me3 can
result from any of the five KMTs listed. SETDB1 converts H3K9me2 to
H3K9me3. Lysine demethylation enzyme families are also listed.

Heterochromatin Protein 1 (HP1)
Heterochromatin protein 1 (HP1) is a heterochromatin-associate protein involved in gene
silencing. HP1 binds to methylated H3K949 and operates in a positive feedback loop. H3K9
methylation stimulates HP1 binding which then recruits more H3K9 methylation. This in turn
forms massive amounts of heterochromatin which further propagates the self-renewal of HP150.
Structurally, HP1 proteins are characterized by a few conserved domains which each have
different roles. The N-terminus chromodomain (CD) binds methylated H3K9, while the C14

terminus chromoshadow domain (CSD) is involved in interactions between proteins. Between
the CD and CDS sits the hinge domain (HD), which binds DNA and linker histone. RNA binding
at the HD is thought to target HP1 to heterochromatin50. In mammals, three isoforms of HP1 are
found localized to various regions. HP1α is localized to pericentromeric heterochromatin, while
HP1β and HP1ϒ are located at both pericentromeric heterochromatin and euchromatin, albeit to
a lesser extent8.
HP1β is associated with mono- and dimethylated H3K9, but not H3K9me351. A knock
out study found HP1β is critical for genome stability, as measured by significant increases in
premature centromere divisions, polyploidy, diplochromosomes, and micronuclei detected
through immunofluorescence8, 52. HP1ϒ, on the other hand, is important for the normal
progression of mitosis8. As for HP1α, the localization has been found to be cell cycle dependent.
As the nuclear envelop breaks down during mitosis, HP1α becomes diffuse, with little
localization to centromeres. It moves between sister kinetochores and then to the spindle
midzone. Specifically, HP1α relocated to centromeres on segregating chromosomes during
anaphase. Once daughter nuclei are formed, HP1α distribution among heterochromatin is
restored53. Because of these different roles, it is important to characterize the binding locations
and functions of HP1 proteins.
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CHAPTER 2
REGULATION OF SETDB1 EXPRESSION BY miR-152-3p

Introduction

In order to assess the effects of miR-152-3p on SETDB1, we chose to either inhibit or
mimic the microRNA and study the resulting consequences at the transcript and protein levels in
human cell lines. We introduced miR-152-3p mimic, a chemically synthesized RNA oligo which
has a sequence identical to miR-152-3p, or anti- miR-152-3p, a chemically synthesized RNA
oligo which has the complementary sequence to miR-152-3p, to cells. By increasing or inhibiting
the miRNA, we can correlate the levels of miRNA to levels of predicted target protein with
western blot analysis. If miR-152-3p represses translation, treating cells with anti-miR-152-3p
would increase SETDB1 protein levels, while miR-152-3p mimic treatment would decrease
SETDB1 protein levels.
It is also worth exploring not just the effect of miR-152-3p on SETDB1 protein, but also
on SETDB1 transcript. If the microRNA affects mRNA stability, significant changes at the
transcript level would correspond to changes at the protein level. Additionally, there is at least
one instance of a miRNA targeting DNA and thus affecting transcription. MiR-324-3p has been
found to target the RelA promoter and induce its expression in an Ago2-mediated way5. In order
to determine if miR-152-3p has any effect on SETDB1 transcript levels, we conducted a qPCR
following anti-miR-152-3p and miR-152-3p mimic treatments.
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We also explored the effects of anti-miR-324-3p on cells due to its high expression in
HCC as compared to the other four experimentally confirmed miRs that target SETDB1 in
humans24 (Figure 2.1). MiR-324-3p is predicted to target SETDB1 as well. We aimed to
compare the effects of miR-152-3p and miR-324-3p on SETDB1.

Figure 2.1 MicroRNAs experimentally determined to target SETDB1.
According to this tree diagram, sourced from miRTarBase, there are five
experimentally confirmed miRNAs that target SETDB1. The three other miR324-3p targets, aside from SETDB1, are also shown24.

HepG2, a human hepatocellular carcinoma (HCC) line, and IMR-91, a normal human
skin fibroblast line were chosen for studying miR-152-3p and SETDB1 due to the presence of
the specific miRNA, mRNA, and protein in the cell lines54, 55. Both miR-152 and SETDB1 have
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also been heavily implicated in HCC12, 23, 54, 56, so IMR-91 was chosen as a normal human cell
line model. HepG2 and IMR-91 have the advantages of being robust, easy to culture, cell lines.

Methods

miRNA Inhibitor and Mimic Transfections
Cells were transfected in parallel with water in lieu of anti-miR or mimic as a negative
control. Multiple time points were repeatedly tested to establish the kinetics of this effect. Cells
were initially assayed 24 hours apart for 3 days upon the user guide suggestion to examine cells
6-72 hours after transfection. When a difference was observed at 24 hours, cells were assayed
every 6 hours for 24 hours.
HepG2 and IMR-91 cells were treated with 50 nM anti-miR-152-3p, 50 nM anti-miR324-3p, 5 nM miR-152-3p mimic, or water on the day of passage using the HiPerFect
transfection reagent according to the Qiagen manual instructions. Briefly, cells were seeded in
cell culture treated plates coated with 0.1% gelatin for IMR-91 cells, or without coating for
HepG2 cells, and incubated under normal growth conditions (37C and 5% CO2) while preparing
transfection complexes. 20 µM stock inhibitor, 20 µM stock mimic, and/or water were diluted in
serum free culture media (IMR-91: DMEM with 4.5 g/L glucose and 100X GlutaMax; HepG2:
DMEM with 1.0 g/L glucose). HiPerFect transfection reagent was added to a final volume of 3%
and tubes were mixed using a vortex. Transfection complexes were formed during a 5-10 minute
room temperature incubation before being added drop-wise onto cells.
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Western Blots for SETDB1 Protein
Total protein was collected in RIPA buffer 6-72 hours after transfection, quantified using
a Lowry assay, and 13.5 µg (Figure 2.2A), 15 µg (Figures 2.2B, 2.3A, and 2.5), or 30 µg
(Figures 2.2C and 2.3B) of protein was loaded on 8% polyacrylamide gels. The gels were run at
120V at 4C and transferred to either nitrocellulose (Figures 2.2C and 2.3B) or PVDF (Figures
2.2A, 2.2B, and 2.3A) at 4C in 40% methanol transfer buffer at 300 mA for 2 hours.
Membranes were blocked in 5% milk/TBST for 1-16 hours and incubated in anti-SETDB1
primary antibody at 1:1000 (Figures 2.2A, 2.2B, and 2.3A) or 1:500 (Figures 2.2C and 2.3B) for
12-16 hours in 5% milk/TBST. Membranes were incubated in anti-mouse secondary antibody for
1 hour at room temperature then visualized under ECL conditions using a Kodak developer.
As a normalization control, membranes were re-probed with anti-β actin primary
antibody for 1 hour at room temperature, then with anti-mouse secondary for 1 hour at room
temperature (Figures 2.2A, 2.2C, 2.3A, and 2.3B). Alternatively, either 2 µg (Figure 2.2B) or 1.5
µg (Figure 2.5) of total protein was loaded on a 10% gel, probed with anti-β actin primary
antibody for 1 hour at room temperature, then with anti-mouse secondary for 1 hour at room
temperature.

qPCR for SETDB1 mRNA
Cells were plated in triplicate for each condition. Total RNA was collected from
trypsinized cells 6-24 hours after treatment using Qiagen’s RNeasy Mini Kit (# 74104) and
quantified with a nanodrop. BioRad’s iScript kit was used to generate 1 µg cDNA/sample. 10 ng
sample and the TaqMan system were used for qPCR. Samples were plated in triplicate and run in
an Applied Biosystems 7500 machine. Technical replicate CT values were averaged for SETDB1
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and β-ACTIN (βACT). βACT values were subtracted from SETDB1 to generate ΔCT. ΔΔCT was
found by subtracting the 0 hour ΔCT from other sample ΔCTs in the time course experiment. In
the single-time point experiment, the water ΔCT was subtracted from SETDB1. Fold change was
then calculated based on the ΔΔCT obtained. 2-way ANOVA with Bonferroni post-test was
performed to determine statistical significance.

Results

Effects of miR-152-3p Inhibitor and Mimic on SETDB1 Protein Levels
Preliminary experiments showed that SETDB1 protein expression decreased 24 hours
after HepG2 cells were transfected with 50 nM anti-miR-152-3p compared to the control
(untreated) sample (Figure 2.2A). In order to identify when the effect was most pronounced, a
time-course experiment was done. Samples were collected every 6 hours for 24 hours posttransfection and analyzed for SETDB1 protein expression. At 6 hours, SEDB1 protein
expression was below the detection threshold of the western blot (Figure 2.2B). We chose the 12
hour time point for subsequent experiments due to the unambiguous reduction in SETDB1 as
compared to the control (dH2O-treated) samples, which still fell within the detectable range.
These results were also seen in IMR-91, a normal human skin fibroblast cells line (Figure 2.3A).
HepG2 cells transfected with miR-152-3p mimic showed an increase in SETDB1 protein at 12
hours after treatment (Figure 2.2C). The same results were also seen in IMR-91 cells (Figure
2.3B).
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Figure 2.2 SETDB1 protein expression in HepG2 cells transfected with antimiR-152-3p, miR-152-3p mimic, and dH2O. HepG2 cells were singletransfected with the described treatment and then collected (A) 24 hours apart for
3 days total (B) 6 hours apart for 24 hours and then 12 hours apart for a total of 72
hours (C) at a single 12 hour time point. Samples were loaded on 8%
polyacrylamide gels and transferred to either NC or PVDF and then probed for
SETDB1 and beta-actin. The water-treated and untreated samples serve as
controls.
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Figure 2.3 SETDB1 protein expression in IMR-91 cells transfected with antimiR-152-3p, miR-152-3p mimic, and dH2O. IMR-91 cells were singletransfected and total protein was collected (A) every 12 hours after treatment for
24 hours and (B) at a single 12 hour time point. Samples were loaded on 8%
polyacrylamide gels and transferred to either NC or PVDF and then probed for
SETDB1 and beta-actin. The water-treated and untreated samples serve as
controls.

Effects of miR-152-3p Inhibitor and Mimic on SETDB1 mRNA Levels
In order to determine if miR-152-3p has any effect on SETDB1 mRNA, we quantified
the steady state levels of SETDB1 mRNA following miR-152-3p manipulation. We transfected
cells with inhibitor, mimic, or water. We collected RNA every 6 hours for 24 hours after a single
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transfection to see if there was any change in SETDB1 mRNA levels in HepG2 cells from the 0
hour, untreated, sample (Figure 2.4, panels A and B). We also collected RNA from both cell
lines 12 hours after a single transfection to determine if there was any change in SETDB1
mRNA levels compared to the water-treated control sample (Figure 2.4, panel C). We found no
significant difference between SETDB1 mRNA levels in dH2O-treated, anti-miR-152-3p-treated,
or miR-152-3p mimic-treated cells in both cell lines (Figure 2.4).
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Figure 2.4 SETDB1 mRNA expression following anti-miR-152-3p and miR152-3p mimic treatment. (A) There was no significant difference in SETDB1
mRNA expression between anti-miR-152-3p and dH2O treated HepG2 cells
across time points. (B) There was no significant difference in SETDB1 mRNA
expression between miR-152-3p mimic and dH2O treated HepG2 cells across time
points. (C) There was no significant difference in SETDB1 mRNA expression
with anti-miR-152-3p or miR-152-3p mimic treatment as compared to dH2O
treatment in HepG2 and IMR-91 cells.
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Effects of miR-324-3p Inhibitor on SETDB1 Protein Levels
We treated cell with miR-324-3p inhibitor to assess the effects of another miRNA
thought to target SETDB1. HepG2 and IMR-91 cells transfected with 50 nM miR-324-3p
inhibitor were assayed 12 and 24 hours after treatment and no decrease in SETDB1 protein was
observed (Figure 2.5).

Figure 2.5 SETDB1 protein expression in cells transfected with anti-miR324-3p and dH2O. Total protein was collected from cells every 12 hours for 24
hours following a single transfection with either anti-miR-324-3p or water.
Samples were loaded on 8% polyacrylamide gels and transferred to PVDF and
then probed for SETDB1 and beta-actin. The water-treated and untreated samples
serve as controls.

25

Conclusions and Discussion

Experimental evidences obtained by western blot analysis of SETDB1 protein expression
and qPCR of SETDB1 mRNA lead us to conclude miR-152-3p positively regulates SETDB1
protein synthesis. We determine miR-152-3p has no effect on steady-state levels of SETDB1
mRNA since qPCR shows no significant changes in SETDB1 mRNA steady-state levels with
and without miR-152-3p mimic and anti-miR-152-3p in both cell lines. Since SETDB1 mRNA
levels do not correspond to the pattern of expression seen in SETDB1 protein levels, we believe
miR-152-3p stimulates synthesis of SETDB1 protein, rather than of SETDB1 mRNA. Our
western blot results for cells transfected with anti-miR-324-3p indicate miR-324-3p may not
target SETDB1.
The effects of miR-152-3p mimic and anti-miR-152-3p were most prevalent at 12 hours
following treatment, but can be seen up to 24 hours post-transfection. Our western blots show
that SETDB1 protein levels return to basal levels over the course of 72 hours after a single
transfection with anti-miR-152-3p. The transient nature of these treatments serves as a technical
limitation in studying the role of miR-152-3p in cells. Because the inhibition or increase of miR152-3p is not constitutive, we can only study the effects within the effective window of the
treatments. We expect that if the miR-152-3p functions by enhancing SETDB1 transcription or
mRNA stability, anti-miR-152-3p treatment would cause a significant decrease in expression of
SETDB1 mRNA, and miR-152-3p mimic transfection would cause a significant increase in
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steady-state levels of SETDB1 transcript. Inhibition of miR-324-3p has no effect on amounts of
SETDB1 protein, as seen in western blots for SETDB1 protein. One of the limitations in this
experiment is the time scale at which we assayed for changes in SETDB1 protein following miR324-3p inhibition.
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CHAPTER 3
EXPLORING THE REGULATION OF miR-152-3p WITH THE SETDB1 3’UTR

Introduction

Currently, the only experimental evidence demonstrating SETDB1 is a miR-152 target
originates from a cross-linking, ligation, and sequencing of hybrids (CLASH) study which found
a binding site for miR-152 in the coding region of SETDB12 (Figure 3.1A). While the technique
of CLASH boasts many advantages such as a < 2% rate of chimeric reads and the ability to
monitor live cell interactions2, it fails to distinguish biologically meaningful interactions from
those which may be transient. This is because CLASH involves crosslinking, which may show
binding of a miRNA to targets it does not actually act on. Thus, it was in our interest to further
explore the interaction between miR-152 and SETDB1 and determine if it their binding
represents a biologically relevant interaction with meaningful consequences in the cell. We chose
to examine the 3’UTR because the experimentally determined binding site for miR-152-3p on
SETDB1 is in a non-canonical region. Moreover, the miRanda database predicted three binding
sites for miR-152-3p on the 3’UTR of SETDB114 (Figure 3.1B).
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Figure 3.1 Confirmed and predicted miR-152-3p binding sites on SETDB1.
(A) CLASH-confirmed binding site in the coding region of SETDB12. (B)
MiRanda Database target recognition sequences (TRS) in the 3’UTR of SETDB1
as shown on miRTarBase14, 24. (C) SETD1 3’UTR structure with TRS 1 (yellow),
TRS 2 (green), and TRS 3 (pink) annotated.

We used a reporter assay to analyze the 3’UTR target sites. Each of the predicted target
recognition sequences (TRS) were individually assessed by deleting those sequences in a
luciferase reporter construct that contains the SETDB1 3’UTR. Beyond solely confirming the
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predicted 3’UTR binding sites, our reporter assay experimental design could also be interpreted
for directionality of targeting. For instance, addition of a 3’UTR to the reporter vector should
decrease luciferase production due to the introduction of miRNA activity, which destabilizes the
luciferase protein. When actual binding sites of a repressive miRNA are mutated, the luciferase
levels should increase as compared to the non-mutated. Conversely, if the binding site of an
enhancing miRNA is disrupted, luciferase levels should decrease. In the case that a TRS is not
real, there would be no change in luciferase upon mutation of the sequence. Two alternative
methods of mutating the binding sites are complete deletion of the site and seed sequence
disruption, which includes base substitution or base deletion.

Methods

Cloning, Transfection, and Luciferase Assay
The backbone vector pmirGLO, also referred to as the empty vector, was purchased from
Promega (Figure 3.2). It contains firefly luciferase (shortened to luciferase, L, or firefly), which
is expressed at different levels depending on the presence, absence, or mutation of an insert.
Luciferase serves as the experimental readout. The vector also contains Renilla luciferase
(shortened to Renilla, R), which is expressed regardless of miRNA activity. Renilla serves as a
readout for transfection efficiency. Vector pmirGLO is ampicillin resistant and has a multiple
cloning site where a miRNA target sequence can be cloned in. The miRNA target sequence
chosen was the SETDB1 3’UTR. It was generated from a HepG2 total RNA sample synthesized
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into cDNA and PCR amplified using primers specific to the SETDB1 3’UTR and vector. The
sequences generated by the InFusion Cloning Primer Design Tool are as follows: forward primer
= 5’- CTA GTT GTT TAA ACG AGG ACA GCC TTC TTC CCA - 3’ and reverse primer = 5’
– GCA GGT CGA CTC TAG CAC AAT CTT ACT TTT ATC ATA TT - 3’. The insert was
cloned into pmirGLO using the InFusion Cloning System (Takara).
The SETDB1 3’UTR insert is 367 base pairs and was analyzed for size on a 1% agarose
gel. Vector linearity was confirmed through agarose gel electrophoresis as well. Once ligated to
the linearized vector, the identity of the insert was verified through DNA sequencing with an
Applied Biosystems 3500 Genetic Analyzer (Appendix II: Supplementary Data).
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Figure 3.2 Overview of SETDB1 3’UTR reporter vector construction. (A)
Original vector map for pmirGLO purchased from Promega (#e1330). (B) Vector
was linearized by digestion with SacI and XbaI restriction enzymes in the
multiple cloning site (MCS). (C) The final MCS sequence contained the 3’UTR
from SETDB1. Cut sites were not preserved. Luciferase expression is driven by
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the PGK promoter. Luciferase levels depend on activity occurring at the 3’UTR
of SETDB1. The SV40 early enhancer/promoter drives Renilla. Renilla is
expressed in every cell transfected with the vector.

Site-directed mutagenesis was performed by designing primer sets to omit the TRS
through PCR amplification. The forward primer is identical to the sequence immediately
following the deletion site. The reverse primer is reverse complementary to the sequence directly
upstream the deletion site and includes a 15 base pair overlap following the deletion site (Table
3.1). Colonies were screened for successful binding site deletion using a PCR approach. Primers
designed to generate a 100 base pair product in the absence of a deletion and approximately 80
base pair product in the presence of a deletion helped us determine which mini preps from
colonies were likely to contain the desired mutation. The final vector sequences were confirmed
through DNA sequencing with an Applied Biosystems 3500 Genetic Analyzer (Appendix II:
Supplementary Data).

Primer Name

Primer Sequence (5’ → 3’)

pE1330S3Upbs1F

CGT TTC CTC AGG AAC TGG GTC TT

SETDB1 3'UTR Sequence Deleted

CCCAACCCTTCTTGAACTGT
pE1330S3Upbs1R GTT CCT GAG GAA ACG AAG AAG GCT GTC CTC TAA AGA AGA C
pE1330S3U2F

TGA ACC CTG ACC CGA AGT CT

pE1330S3Upbs2R

TCG GGT CAG GGT TCA TCC TGA GGA AAC GAC AGT TCA AGA A

pE1330S3Upbs3F

TAG CAG GCA GGA TCC CTT CTC

pE1330S3Upbs3R

GGA TCC TGC CTG CTA CTG GTC CAG AAC CCC CAT TTC

ACTGGGTCTTCCTGATTGT

ATGATCCCTTCCAATGTGGTGC

Table 3.1 Primer sets designed to generate target recognition sequence
deletions within the 3’UTR of SETDB1. The primer name listed is the name the
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primer was order under and is labeled as in the -20C freezer where it is stored.
The primer sequence provided was created based on the rules for generating sitedirected mutagenesis using the InFusion Cloning Kit (Takara). Each primer pair
generated one of three deletions, as shown in this table.

HepG2 and IMR-91 cells were plated on day 0 at 10,000 cells per well of a white-wall
96-well cell culture treated dish with 0.1% gelatin coating for IMR-91 cells only under aseptic
conditions and allowed to adhere overnight in a 37C humidified incubator with 5% CO2. On
day 1, cells were transfected with DNA using Lipofectamine 2000 according to the product
protocol. Transfection parameters were first optimized for timing and reagent concentrations by
treating cells with 100 ng DNA diluted in Opti-MEM and the following amounts of
Lipofectamine 2000 reagent diluted in 25 µL Opti-MEM: 0.2 µL, 0.3 µL, 0.4 µL, or 0.5 µL.
Optimal transfection parameters were determined by comparing the empty vector background
subtracted luciferase/Renilla ratio to the vector with SETDB1 3’UTR background subtracted
luciferase/Renilla ratio 24 hours after transfection (Appendix II: Supplementary Data). It was
determined that 0.4 µL Lipofectamine was the ideal quantity to use and all other transfections
were done with this amount. After optimization, HepG2 cells were evaluated for miRNAmediated effects on luciferase expression by comparing the empty vector background subtracted
luciferase/Renilla ratio to the vector with SETDB1 3’UTR background subtracted
luciferase/Renilla ratio. The ratio of the empty vector represented a maximum value.
On day 2, cells were assayed using the Dual-Glo Luciferase Assay System from
Promega. Cells and reagents were equilibrated to room temperature. Dual-Glo reagent was added
to each well and incubated at room temperature for at least 10 minutes. During this time, cells
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lysed, allowing for firefly luminescence to be measured using an LMAX II Luminometer
(Molecular Devices). Next, Stop and Glo Reagent was added to each well. The plate was again
incubated at room temperature for at least 10 minutes before measuring Renilla luminescence on
the luminometer. This protocol is summarized in Figure 3.3.

Figure 3.3 Timeline and overview of protocol for transfecting HepG2 cells
with reporter vector. This image was modified from the Lipofectamine 2000
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protocol provided by Invitrogen. Cell seeding occurred 1 day prior to cell
transfection and luminescence was read 1 day following transfection.

In order to account for non-specific fluorescence as a result of auto fluorescence or
reagent fluorescence, wells on each plate were mock transfected using Opti-MEM only. These
cells were otherwise treated identically to DNA-transfected cells by using the same growth
conditions. When Dual-Glo was applied, background luciferase values were obtained. Addition
of Stop and Glo created a Renilla background value. The luciferase background values were
averaged for each trial and subtracted from each well’s luciferase value. Next, the background
subtracted luciferase value/Renilla was taken. This luciferase/Renilla (also referred to as
firefly/Renilla) ratio allows us to compare values across trials. To ensure the reproducibility and
reliability of background subtracted luciferase/Renilla ratios, a minimum of three independent
trials were done with a minimum n=3 per condition in each trial.

Results

Experimentally Assessing Computationally Predicted miR-152-3p binding sites in the 3’UTR of
SETDB1
The empty vector firefly/Renilla luminescence ratio represented the absence of all miR
activity, as there was no miR target site present. By adding in the 3’UTR from SETDB1,
miRNAs could potentially bind to all available target sites within the region. An unpaired t-test
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showed the firefly/Renilla luminescence ratio was significantly lower in HepG2 (p < 0.0001) and
IMR-91 (p < 0.001) upon addition of the SETDB1 3’UTR, representing miR activity across the
entire UTR. Our data shows miR binding has been disrupted in two of the three miR-152-3p sites
predicted by miRanda to exist in the 3’UTR of SETDB1 in HepG2 cells only.
In IMR-91 cells, there were no significant changes (p > 0.01) in firefly/Renilla
luminescence with any of the target recognition sequence deletions. In HepG2 cells, when target
recognition sequence 1 was removed (TRSΔ1), a significant decrease (p < 0.001) in
firefly/Renilla luminescence was observed. When target recognition sequence 2 was deleted
(TRSΔ2), no significant changes occurred. When the third target recognition sequence was
deleted (TRSΔ3), the firefly/Renilla luminescence ratio was significantly higher (p < 0.01) than
the vector with un-mutated SETDB1 3’UTR (Figure 3.4).

A.
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B.

Figure 3.4 Sequence requirements for regulatory activity on the 3’UTR of
SETDB1. For all data, significance was determined with unpaired t-test to vector
containing SETDB1 3’UTR. (A) In IMR-91 cells, there was a significant decrease
(p < 0.001) in

luciferase/Renilla luminescence ratio (L/R) upon addition of the

SETDB1 3'UTR. (B) In HepG2 cells, there was also a significant decrease (p <
0.0001) in L/R upon addition of the SETDB1 3'UTR. L/R was significantly lower
(p < 0.001) with the TRSΔ1 mutation, and significantly higher (p < 0.01) with the
TRSΔ3 mutation.
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Conclusions and Discussion

We provide the first experimental evidence of miRNA regulatory activity on the 3’UTR
of SETDB1. Overall, addition of the 3’UTR to the empty vector resulted in a significant (p <
0.001) decrease in firefly/Renilla as compared to the empty vector alone. This change, which
was observed in both cell lines, represents the net effect of all regulatory activity on the entire
3’UTR of SETDB1. We found the firefly/Renilla value decreased with target recognition
sequence (TRS) 1 deletion and concluded TRS 1 is required for regulation of SETDB1 in HepG2
cells. Deletion of TRS 2 caused no significant changes in luciferase as compared to the vector
containing intact 3’UTR. Thus, TRS 2 may not be required for regulation of SETDB1 in HepG2
cells. When TRS 3 was deleted, the firefly/Renilla luminescence ratio was significantly higher (p
< 0.01) than the vector with un-mutated SETDB1 3’UTR in HepG2 cells.
Deletion of the individual target recognition sequences presented different results in each
cell line. Since the vectors were the same and the only difference was the cell type, these results
may signify a cell type-specific finding. Our data might reflect different miRNA content and
expression in different cell lines. In IMR-91 cells, deletion of target recognition sequences 1 and
3 caused no significant change in luciferase/Renilla activity. A possible explanation would be
that these are not true binding sites for miR-152-3p. However, removal of TRS 1 or TRS 3
resulted in significant changes (p < 0.001 and p < 0.01, respectively) in luciferase/Renilla in
HepG2 cells. This paradox leads us to question how these cell line differences can arise. One
possibility is that the predominant binding sites for miR-152-3p may be different in different cell
lines. Perhaps miR-152-3p largely targets the CDS in some cells and the 3’UTR in others. This is
feasible since other miRNAs bind in these regions, but expression of them can vary across tissue
39

types. Thus, in one cell line, less miR-152-3p may bind in the 3’UTR due to greater activity from
other miRNAs binding at that same location.
Another possible interpretation is that there could be different expression levels of
different miRNAs in the different cell lines. This possibility seems likely given that there is
evidence of tissue-specific expression of miRNAs1. Moreover, there could even be the same
expression of different miRNAs which target those regions with different functions. For
example, if a repressive miRNA is expressed highly in IMR-91 and an enhancer miRNA is
expressed highly in HepG2 cells, both of which target the deleted site, we may still obtain
significant changes in luciferase with site-directed mutagenesis in HepG2 cells and no changes in
luciferase with site-directed mutagenesis in IMR-91 cells. It is worth noting that there are
presently no predicted or confirmed repressive miRNAs targeting TRS 1, and searches on
RNA22 and microRNA.org yield no miRNAs which could bind to the TRS 1 sequence (5’CCCAACCCTTCTTGAACTGT-3’).
Finally, another potential interpretation is that if there are different expression levels of
the same miRNA in HepG2 and IMR-91 cells, we may still see cell line differences. For
example, when looking at the predicted miRNAs binding at TRS 3 (Figure 3.5), if it were
confirmed that all three miRNAs, miR-152-3p, miR-1260b, and miR-324-3p bind at TRS 3, but
the levels were different of these miRNAs in each cell line, site-directed mutagenesis of TRS 3
might cause significant changes in luciferase in HepG2 cells and no changes in luciferase with
site-directed mutagenesis in IMR-91 cells. As a hypothetical scenario under this potential
interpretation, if miR-1260b is SETDB1 repressive in both cell lines, but is highly expressed in
HepG2 cells and expressed at very low levels in IMR-91, and miR-324-3p and miR-152-3p
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levels are constant in both cell lines, there may be a significant increase in luciferase with sitedirected mutagenesis of TRS 3 in HepG2 cells with no change in IMR-91 cells.
Deletion of TRS 1 or TRS 3 was found to bear significant effects on luciferase/Renilla (p
< 0.001 and p < 0.01, respectively) when compared to the empty vector in HepG2 cells.
However, their effects were significant in opposing directions. In order to understand these
contrasting results, the effects of other miRNAs thought to target at those sites must be
considered (Figure 3.5).
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Figure 3.5 MiRNA binding sites in the SETDB1 3’UTR. All miRNAs listed in
this figure are determined to target SETDB1 by Helwak, et. al. using CLASH2;
however, the annotated sequences shown are predicted by miRanda. TRS 1 is
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highlighted in yellow, TRS 2 is highlighted in green, and TRS 3 is highlighted in
purple. TRS 1, 2, and 3 were deleted using site-directed mutagenesis to form 3
mutant vectors. Deletions of these sites were performed to help determined the
necessity of those sequences for SETDB1 regulation.

At TRS 1, there are presently no other miRNAs besides miR-152-3p predicted to target at
this site. Since the luciferase/Renilla value decreased with TRS 1 deletion, we believe miR-1523p is positively regulates SETDB1 protein. If the luciferase/Renilla value had remained
unchanged, we would conclude miR-152-3p does not target at TRS 1. If the luciferase/Renilla
value had significantly increased, we would conclude that miR-152-3p is repressive of SETDB1.
In contrast to there being no other miRNA binding site overlaps at TRS 1, there are two
other miRNAs predicted by miRanda to bind at TRS 3. If we assume that these other miRNAs,
miR-1260b and miR-324-3p, are SETDB1 repressive and that at least one of them represents a
biologically meaningful interaction with SETDB1, deletion of the site would significantly
increase luciferase/Renilla. This is precisely what was observed. Interestingly, the
luciferase/Renilla level doesn’t identically match the empty vector value. Possible interpretations
are that this may be due to experimental variation, as the difference is not significant, or that it
may represent the counter-effects of miR-152-3p on SETDB1. Under the pretense that miR1260b and/or miR-324-3p are SETDB1 repressive, whether miR-152-3p binds at TRS 3 or not,
we might observe the same significant increase in luciferase/Renilla that was obtained. For this
to be the case, equal activity of all miRs on TRS 3 would have to be assumed. Thus, we can
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eliminate the possibility that miR-152-3p activity is greater than that of miR-1260b or miR-3243p at TRS 3.
Though it was previously found that miR-324-3p targets SETDB12, our reporter assay
findings in combination with anti-miR-324-3p transfection and subsequent SETDB1 protein
analysis do not entirely support a meaningful biological interaction between the two. Since the
TRS 3 deletion results would be the same even without miR-324-3p binding, and inhibition of
miR-324-3p had no noticeable effect on SETDB1 protein, it may be that the interaction between
miR-324-3p and SETDB1 is transient with no downstream effects.
Based on the results obtained upon deletion of TRS 2, we can infer one of two things:
either miR-92a and miR-152-3p bind and have opposite regulatory functions, such that miR-92-a
is a negative SETDB1 regulator and miR-152-3p is a positive SETDB1 regulator, or that neither
miRNA binds to TRS 2. Binding of miRNAs at TRS 2 must be “all or none” simply because
these are the only two scenarios, based on the available information, which would result in
insignificant findings. Since the results from TRS 1 deletion indicate that miR-152-3p is a
positive regulator, a successful interaction at TRS 2 would also show a significant decrease in
luciferase/Renilla. Conversely, if miR-92a alone binds and does so in a repressive manner, there
would be a significant increase in luciferase/Renilla. If both miRNAs bind with the described
functions and at equal efficiencies, their activities would net no impact on the luciferase/Renilla
luminescence. Thus, we can infer that either both miRNAs bind at TRS 2 with opposing
functions, or neither miRNA binds at TRS 2. In any case, neither of the miRNAs bind alone to
TRS 2. These considerations hold true in both cell lines since deletion of TRS 2 was not
significant in IMR-91 and HepG2 below p < 0.01.
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One experiment that we’ve omitted in this study is to co-transfect cells with miR-152-3p
mimic or anti-miR-152-3p and the reporter vector. Doing so may have allowed us to more
directly study the effects of miR-152-3p on SETDB1. However, we predicted that if miR-152-3p
was inhibited, the effects of other miRNAs that bind to the SETDB1 3’UTR would have
dominated. If cells were transfected with miR-152-3p mimic, it may have been possible to get
more miR-152-3p binding to the 3’UTR. On the other hand, it is also possible that what we
observed was already the maximal binding capacity of miR-152-3p to SETDB1, and adding
mimic may not make any difference. Moreover, treatment with anti-miR and mimic needed to be
done on the same day as cell seeding, according to the HiPerFect transfection reagent protocol.
Then, it took 12 hours post-transfection to see an effect with either anti-miR or mimic, as
determined by our own experiments. This timeline was incompatible with the vector transfection
and assay timeline, which required cells to be adherent upon transfection, and luminescence was
measured on day 2. Thus, given the likelihood that no new knowledge would be obtain through
co-transfection and the challenge of weaving together different timelines, this experiment was
not pursued.
Another strategy for demonstrating miR-152-3p binding to the SETDB1 3’UTR would
have been to do a miRNA binding experiment, such as CLASH. These types of experiments rely
on pull downs of miRNA with targets. However, because they are accomplished on fixed cells,
the biological relevance of results comes into question. This is particularly true because CLASH
does not provide a way to distinguish transient interactions from stable interactions. Therefore, it
is essential to employ multiple approaches when confirming a potential miRNA interaction.
Furthermore, Helwak, et. al. and others concede that that non-canonical binding sites may not
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even be functional2, 57. While the technique of CLASH yields only 2% non-specific binding2, the
biological relevance of targets obtained is unclear.
One of the biggest issues with using the SETDB1 3’UTR to study miR-152-3p binding is
that there are five other miRNAs which are experimentally confirmed to bind to SETDB1 and
predicted to do so at the 3’UTR, and numerous predicted miRNAs, that bind in this 367 base pair
region. Several of these binding sites overlap with the miR-152-3p TRSs, confounding the
luciferase reporter assay results (Figure 3.5). Since it is not practical to inhibit every miRNA that
may bind to the 3’UTR, additional mutation studies could be done. For example, truncating the
3’UTR after the last miR-152-3p target recognition sequence would eliminate some of the other
miRNA binding sites. Another option would be to clone in only the target recognition sequences,
one per luciferase reporter vector to see the specific effect of miR-152-3p activity on those sites.
Alternatively, each binding site could sustain point mutations at the seed sequence to see if there
is any impact on luciferase activity. Perhaps through doing multiple mutation studies, additional
evidence supporting miR-152-3p binding and negative regulation of SETDB1 translation could
be found. However, we primarily relied on miR-152-3p mimic and anti-miR-152-3p treatment
followed by western blot analysis of SETDB1 protein for assessing directionality of the
miRNA’s function, and used the reporter vector results to confirm our western blot results.
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CHAPTER 4
EFFECTS OF miR-152-3p REGULATION OF SETDB1 ON HISTONE METHYLATION

Introduction

It is well-established that SETDB1 methylates H3K9me2, thereby producing H3K9me3.
Since inhibition of miR-152-3p caused SETDB1 protein levels to decrease compared to watertreated cells, we sought to determine if H3K9me3 levels would also be reduced with anti-miR152-3p treatment relative to water treated cells. Conversely, when cells were treated with miR152-3p mimic, we saw an increase in SETDB1 protein compared to water-treated cells. Thus, we
predicted that H3K9me3 levels would increase in the presence of miR-152-3p mimic relative to
water treated cells. Since H3K9me2 serves as the substrate for SETDB1, levels for H3K9me2
and SETDB1 should be inversely linked under miR-152-3p perturbation. Specifically, we
predicted miR-152-3p mimic treatment would decrease H3K9me2 levels compared to watertreated cells and anti-miR-152-3p treatment would cause H3K9me2 levels to increase compared
to water treated cells. To study the levels of H3K9me2/3, we performed anti-miR and mimic
treatments followed by a histone ELISA for H3K9me2/3. Changes in H3K9me2/3 levels as a
result of miR-152-3p inhibitor or mimic would indicate that miR-152-3p has an indirect role in
epigenetic gene regulation.
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Figure 4.1 Relationship between miR-152-3p, SETDB1, and H3K9me2/3.
MiR-152-3p targets SETDB1 mRNA. MiR-152-3p affects the translation of
SETDB1, an enzyme which converts H3K9me2 to H3K9me3.
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Methods

Preparation of Histones
106 cells were transfected according to standard procedures with 50 nM anti-miR-152-3p,
5 nM miR-152-3p mimic, or water. 12 hours after transfection, cells were trypsinized, washed in
PBS, and then resuspended in 0.4 M HCl. Cells were incubated on ice for 30 minutes with
occasional mixing. Lysate was centrifuged at 11,000 x g for 10 minutes at 4C. The supernatant
was collected and 2/5 the total volume of neutralization buffer (1M NaPO4 dibasic, pH to 12.5
using 5 M NaOH, 2.5 mM DTT, and 10 mM PMSF, sometimes substituted with Halt Protease
Inhibitor, Thermo Fisher Scientific, #78430) was immediately added. Histones were then
aliquoted into single-use portions and stored at -80C. A Lowry assay was used to quantify
histones. Typical histone yields ranged from 0.70 µg/µL to 1.5 µg/µL.

H3K9me2 and H3K9me3 Enzyme-Linked Immunosorbant Assay (ELISA)
Pre-coated H3 capture ELISA plates were obtained from Active Motif for H3K9me2 and
H3K9me3 analysis. Crude histone samples were plated and assayed according to kit instructions.
In addition to measuring H3K9me2 and H3K9me3 in samples, we also purchased unmethylated
H3 isolate from Active Motif to serve as a negative control for the ELISA. Samples were run in
triplicate with a range of concentrations. The standard curve was performed in duplicate on each
plate.
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H3 from crude histone samples was bound to plates with incubation for 1 hour at room
temperature. The plate was washed 3 times with wash buffer, then incubated in primary antibody
for 1 hour at room temperature with agitation. Afterwards, the plate was washed 3 times with
wash buffer. Next, secondary antibody was bound for 1 hour at room temperature without
agitation. The plate was washed 3 times with wash buffer prior to beginning the colorimetric
reaction.
Developing solution was added to each well and samples were incubated for
approximately 30 seconds to 5 minutes under low light until standard curve wells appeared
medium to dark blue. At this point, stop solution was added to wells and the absorbance was read
at 450 nm (assay wavelength) and 655 nm (reference wavelength).

Data Analysis
Data was processed by first subtracting the reference wavelength absorbance value from
the assay wavelength absorbance value. Then, the absorbance value for the blank was subtracted
from each value. The final absorbance values for the standard curve wells were plotted against
the known concentrations. Linear regression created a line of best fit and an equation which was
then used to determine the concentrations of H3K9me2/3 in the samples. T-tests were used to
determine statistical significance.
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Results

ELISA Controls
No non-specific antibody binding to H3 was observed with H3K9me2 (Figure 4.2) or
H3K9me3 (Figure 4.3). We also found significantly higher (p < 0.0001) H3K9me2 and
H3K9me3 levels in HepG2 cells than in IMR-91 cells (Figure 4.4).

Figure 4.2 Histone H3 and H3K9me2 ELISA results. Unmethylated H3 and
H3K9me2 were plated in duplicate at 0 ng/well and 2-fold concentrations ranging
from 7.8 ng/well to 500 ng/well for an ELISA measuring H3K9me2. There is
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high specificity for H3K9me2, as shown through the background (Opti-MEM
only wells) subtracted absorbance values. By contrast, very little to no signal is
seen for H3.

Figure 4.3 Histone H3 and H3K9me3 ELISA results. Unmethylated H3 and
H3K9me3 were plated in duplicate at 0 ng/well and 2-fold concentrations ranging
from 7.8 ng/well to 500 ng/well for an ELISA measuring H3K9me3. There is
high specificity for H3K9me3, as shown through the background (Opti-MEM
only wells) subtracted absorbance values. By contrast, very little to no signal is
seen for H3.
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Figure 4.4 Steady state levels of H3K9me2/3 in cell lines. HepG2 cells have
significantly more (p < 0.0001) H3K9me2 and H3K9me3 than IMR-91 cells.

Effects of miR-152-3p Regulation of SETDB1 on H3K9me2/3
Anti-miR-152 treatment of HepG2 cells caused a significant increase (p < 0.0001) in
H3K9me2 levels compared to water-treated cells, and no change in H3K9me3 levels compared
to water-treated cells (Figure 4.5). Likewise, in IMR-91 cells, there was no significant change in
H3K9me3 levels with anti-miR-152-3p treatment compared to water treated cells (Figure 4.6).
MiR-152-3p mimic treatment of HepG2 cells caused a significantly decreased (p < 0.05)
in H3K9me2 levels compared to water-treated cells, and a significant increase (p < 0.05) in
H3K9me3 compared to water-treated cells (Figure 4.5). In miR-152-3p mimic treated IMR-91
cells, H3K9me2 levels significantly increased (p < 0.05) and H3K9me3 levels significantly
decreased (p < 0.05) (Figure 4.6).
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Figure 4.5 ELISA results for H3K9me2/3 levels in HepG2 cells. H3K9me2
levels significantly increase (p < 0.0001) with anti-miR-152 treatment and
significantly decrease (p < 0.05) with miR-152-3p mimic treatment in HepG2
cells as compared to water treated HepG2 cells. H3K9me3 levels significantly
increase (p < 0.05) in miR-152 mimic treated HepG2 cells relative to water
treated HepG2 cells.
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Figure 4.6 ELISA results for H3K9me2 and H3K9me3 levels in fibroblasts.
H3K9me2 levels significantly increase (p < 0.05) in miR-152 mimic treated IMR91 cells, but H3K9me3 levels significantly decreased (p < 0.05) with miR-152-3p
mimic treatment relative to control (water treated) IMR-91 cells. The effects of
anti-miR-152-3p treatment on H3K9me2 and H3K9me3 were not significant
when compared to control cells in fibroblasts.
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Conclusions and Discussion

As predicted, H3K9me2 significantly increased (p < 0.0001) with anti-miR-152-3p
treatment and H3K9me3 levels significantly increased (p < 0.05) with miR-152-3p mimic
treatment in HepG2. Under anti-miR-152-3p treatment, miR-152-3p was inhibited and could no
longer bind to or positively regulate SETDB1. With less SETDB1 present, there may have been
a reduced turnover from H3K9me2 to H3K9me3. This may be why we saw more H3K9me2 with
anti-miR-152-3p treatment and no change in H3K9me3, of which there might have been a preexisting pool. The opposite held true with miR-152-3p mimic treatment; there may have been
more miR-152-3p present to upregulate SETDB1, which then may have increased turnover from
H3K9me2 to H3K9me3. Therefore, there was a significant decrease in H3K9me2, and a
significant increase in H3K9me3 with miR-152-3p mimic treatment.
Ultimately, we found that miR-152-3p regulation of SETDB1 proportionately impacts
histone methylation. Decreases in SETDB1 caused by anti-miR-152-3p treatment resulted in
increases in H3K9me2. Conversely, increases in SETDB1 caused by miR-152-3p mimic
treatment corresponded to increases in H3K9me3. Therefore, miR-152-3p regulation of SETDB1
affects levels of the modified histone proteins involved in epigenetic gene silencing in HepG2
cells. Furthermore, the regulation of SETDB1 by miR-152-3p is biologically relevant in HepG2
cells due to these effects on H3K9me2/3.
Though we predicted anti-miR-152-3p treatment would elicit a decrease in H3K9me3, it
did not do so. Instead of undermining our hypothesis, we believe this finding exposes a
limitation in the experimental design. Because cells were grown, treated, then assayed for
modified histone, there was no way to distinguish H3K9me2 or H3K9me3 resulting directly
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from treatment from existing H3K9me2 or H3K9me3. We only knew there was an effect based
on statistically significant differences from the control. With this understanding, we speculate
that anti-miR-152-3p did not impact H3K9me3 because H3K9me3 was already present.
Therefore, the H3K9me3 values for anti-miR-152-3p treated HepG2 cells represented a preexisting pool of the modified histone.
The best way to address the pre-existing pool of modified histones would be to perform
radio-labeling experiments. This way, the newly synthesized H3K9me2 or H3K9me3 would
possess an isotope label to allow us to distinguish it from pre-existing H3K9me2 or H3K9me3.
In addition to radio-labeling experiments, there are several alternative approaches for the study
of histone modifications instead of the histone ELISA we utilized. However, all of these
techniques suffer from an inability to distinguish newly modified histones from previously
existing histone modifications.
Western blot would have been the least expensive method for observing overall effects of
treatment on cells if already optimized. However, it is not directly quantitative in nature and
would not provide a statistical analysis of differences. Flow cytometry can also be done to look
at histone modifications59. With optimization, this would have been a valid method as it is both
quantitative and allows for statistical analysis of differences. One final technique that could have
been used for studying histone modifications is quantitative mass spectrometry. This method was
not chosen as it requires specialized knowledge of mass spectrometry. ELISA was used to study
histone modifications as it is quantitative, rapid (3.5 hour procedure), and more cost effective
than western blotting since the kit and reagents are already optimized.
Interestingly, the same changes seen in H3K9me2 and H3K9me3 levels in HepG2 cells
were not seen in IMR-91 cells. In fact, anti-miR-152-3p treatment had no significant effect on
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H3K9me2 or H3K9me3. Yet, miR-152-3p mimic treatment significantly affected both H3K9me2
and H3K9me3 in fibroblasts, but in opposite directions. Notably, HepG2 cells are derived from a
15 year old human with hepatocellular carcinoma, while IMR-91 comes from healthy human
fetal skin fibroblasts. The different results from each cell line may indicate the healthy cells
respond to increases in SETDB1 levels differently than the cancer-derived HepG2 cells. Since
SETDB1 has also been found to have roles in mono- and dimethylation of H3K936, 37, it may be
that these actions are at play rather than the trimethylating activity of SETDB1. Another strong
possibility is that what we observe in IMR-91 cells is akin to background H3K9me2/3, since
neither is present at very large quantities in these fibroblasts (Figure 4.4).
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CHAPTER 5
EFFECTS OF miR-152-3p POSITIVE REGULATION OF SETDB1 PROTEIN ON HP1α

Introduction

Having shown that miR-152-3p targeted the 3’UTR of SETDB1, upregulated SETDB1
protein, decreased H3K9me2, and increased H3K9me3, we were interested in determining if
there was any effect on heterochromatin protein 1 (HP1). HP1 is a structural protein recruited by
H3K9me3 and involved in the formation of heterochromatin (Figure 5.1). Of the three isoforms,
HP1α was chosen for study due to its localization to constitutive heterochromatin8.
We predicted that because H3K9me3 levels increased with miR-152-3p mimic treatment,
HP1α levels in the nucleus would also increase with miR-152-3p mimic treatment. Likewise, we
predicted less HP1α to be recruited to histones with anti-miR-152-3p treatment. In this case,
HP1α would appear decentralized (not attached to histones or DNA) under immunofluorescence.
The reason we predicted HP1α would be decentralized with anti-miR-152-3p treatment is
because there was less H3K9me3 than with miR-152-3p mimic treatment. However, as we saw
in our ELISA results, there may be a pre-existing pool of HP1α, thereby confounding our results.
We visualized HP1α under inverted microscopy and replicated the imaging in HepG2
cells using confocal microscopy and fluorescent intensity analysis. Since localization of HP1α is
cell cycle dependent7, 53, cell cycle analysis with flow cytometry was done. This allowed us to
distinguish fluctuations in HP1α due to cell cycle progression from fluctuations resulting from
anti-miR-152-3p or miR-152-3p mimic transfection.
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Figure 5.1 Recruitment of HP1α. (A) miR-152-3p upregulates SETDB1, which
trimethylates H3K9me2 and forms H3K9me3. The N-terminus chromodomain of
HP1α binds to H3K9me3, while the hinge domain of HP1α binds DNA and linker
histone. (B) H3K9me3 and HP1α binding at H3K9me3 stimulate subsequent
HP1α

recruitment.

(C)

As

HP1α

binds,

heterochromatin

is

formed.

Heterochromatin formation recruits additional HP1α.

Methods

HP1α Immunofluorescence
For inverted microscopy, cells were grown in a 12-well cell culture treated plate for 12
hours after transfection with anti-miR-152-3p, water, or miR-152-3p mimic. Cells were washed
in PBS, fixed in 4% PFA/PBS for 15 minutes, then washed 3 times with 1% BSA/TBS.
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Permeabilization was done with 0.25% Triton X-100/TBS for 10 minutes. Cells were then
blocked in 5% goat serum/TBS for 1-3 hours at room temperature. They were incubated in 1:400
anti-HP1α antibody (ab9057) for 16 hours at 4C. Next, cells were washed 3 times in 1%
BSA/TBS and incubated in Alexa 488 secondary at 1:800 for 1 hour at room temperature. Cells
were then washed, DAPI stained, and washed again prior to visualization. For confocal
microscopy, the protocol was identical with the exception that cells were grown on cell culture
treated chamber slides (Ibidi).
For all immunofluorescence, cells were plated in triplicate. Images were taken from
across each well beginning with the DAPI setting, so as not to allow the HP1α signal to influence
image selection. For fluorescence intensity analysis using confocal microscopy, each field
contained a minimum of 1 dozen cells from which data could be collected. Cells where discrete
nuclei could not be distinguished were omitted from statistical analysis. Region of interest (ROI)
boxes of uniform area were drawn at the center of nuclei under FITC and DAPI. Fluorescent
values were then recorded. This was done for over 78 water treated cells, 75 anti-miR-152-3p
treated cells, and 94 miR-152 mimic treated cells. One-way ANOVA was done to determine
mean differences between groups. Cells stained with the primary antibody omitted were also
visualized to provide a background control.

HP1α Flow Cytometry and Cell Cycle Analysis
106 cells per condition were grown in 6-well cell culture treated plates. Cells were
trypsinized and washed then fixed with 70% ethanol at -20C. Cells were permeabilized with
0.1% Tween-20 in PBS for 20 minutes at room temperature. They were then incubated in
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primary antibody (anti-HP1α, ab9057) for 20 minutes at a dilution of 1:50. Secondary staining
with Alexa 647 occurred for 20 minutes at a dilution of 1:400. Cells were RNase treated prior to
propidium iodide (PI) staining and analyzed using a BD LSRFortessa X-20.
Unstained water treated HepG2 cells, antibody (HP1α + Alexa 647) stained water treated
HepG2 cells, and propidium iodide (PI) stained water treated HepG2 cells were chosen as
compensation controls for flow cytometry. Cells treated with anti-miR-152-3p and miR-152-3p
mimic were plated in duplicate to allow one set of cells for each condition to be stained with
secondary antibody (Alexa 647) plus PI and the other set to be stained with HP1α, Alexa 647,
and PI. These two staining conditions were also done for water treated cells. Using this
combination of parameters allows us to look at the expression of HP1α at G0-G1, S, and G2-M
stages of the cell cycle. PI stains all nucleic acids, thus, cells were RNase treated prior to PI
staining to ensure DNA-specific staining.

Results

Effects of miR-152-3p Regulation of SETDB1 on HP1α
HP1α images from inverted microscopy can be found in Appendix II: Supplementary
Data. These images were selected and organized by Madeline Dorso (2016). Images from
confocal microscopy are presented in Figure 5.2. A single representative image is shown per
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identically-treated replicate well (R1-R4). When quantified, anti-miR-152-3p treated HepG2
cells had a significantly higher (p < 0.0001) HP1α intensity/area than water treated HepG2 cells,
as shown by FITC staining (Figure 5.3). Raw ROI values were obtained by Madeline Dorso
(2016).
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Figure 5.2 HP1α localization in HepG2 cells fixed 12 hours post-transfection.
All wells were visualized under a Nikon A1R Spectral Confocal Microscope.
Representative cells from replicate wells are shown in horizontal panels as R1,
R2, R3, and R4. HP1α was visualized under the FITC channel. (A) HepG2 cells
mock transfected with water. (B) HepG2 cells transfected with anti-miR-152-3p.
(C) HepG2 cells transfected with miR-152-3p mimic.
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Figure 5.3. Nuclear HP1α staining intensity in HepG2 cells. HP1α was
quantified by fluorescent intensity in the FITC channel using NIS Elements.
Fluorescence from the FITC channel was calculated by first subtracting the
background fluorescence from the raw FITC values and then by dividing the
background subtracted value by the area of the ROI. Statistical analysis by oneway ANOVA found a significance of p < 0.0001 for anti-miR-152-3p treated cells
compared to water treated cells.

Flow cytometry data showed that amounts of HP1α increased throughout the cell cycle
stages G0-G1, S, and G2-M in control, water-treated, cells. We also found that HP1α levels
increased across both experimental treatment conditions, anti-miR-152-3p and miR-152-3p
mimic, for each of the cell cycle stages. Because there was only one sample per condition,
statistical significance could not be determined (Figure 4.9).
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Figure 5.4. HP1α levels in treated HepG2 cells across stages of the cell cycle.
HepG2 cells were treated with either water, anti-miR-152-3p, or miR-152-3p
mimic for 12 hours before being fixed for flow cytometry with a BD LSRFortessa
X-20 instrument. One sample was collected for each treatment condition. The
corrected mean HP1α fluorescence was calculated by subtracting the APC-A
mean for samples stained with anti-HP1α primary antibody, Alexa 647 secondary
antibody, and propidium iodide from the APC-A mean for samples stained only
with Alexa 647 secondary antibody and propidium iodide.
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Conclusions and Discussion

Overall, there was no discernable difference in HP1α localization among treatment
conditions as visualized under confocal microscopy. With confocal microscopy, we concluded
HepG2 cells mock transfected with water showed an even dispersion of HP1α in the nucleus and
cytoplasm (Figure 5.2A). We also concluded that HepG2 cells transfected with anti-miR-152-3p
appeared to have an increased amount of HP1α in both the nucleus and cytoplasm compared to
water treated cells, with even staining in both regions, rather than changes in localization (Figure
5.2B). Finally, we concluded that HepG2 cells transfected with miR-152-3p mimic did not seem
to have a clear pattern of HP1α location or abundance relative to water or anti-miR-152-3p
treated cells (Figure 5.2C).
We noticed a difference in staining intensity of HP1α across samples such that cells
treated with anti-miR-152-3p had significantly higher FITC staining (p < 0.0001) under
immunofluorescent microscopy. We hypothesized that this may have been due to an increase in
the quantity of HP1α, better detection of HP1α in those wells each time, or that miR-152-3p
affected cell cycle progression. Since there is an established paradigm between HP1α levels and
stage in the cell cycle, we looked at the effects of miR-152-3p on HP1α with flow cytometry. We
found that HP1α levels increased across all treatments. As neither our previous work nor the
literature can provide a suitable explanation for the observations that both anti-miR-152-3p and
miR-152-3p mimic treatments increase HP1α throughout the cell cycle, we concluded that miR152-3p may not actually bear an effect on HP1α. Instead, changes in HP1α localization or
quantity observed across treatments could be due to the inherent fluctuations in HP1α described
by Sugimoto, et al.53. It is worth noting that there is bleed over from each phase when doing cell
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cycle analysis. Thus, if a true S-phase is to be seen, an additional stain such as PCNA should be
used. For our purposes, a clear S-phase was not necessary.
While the effects on H3K9me2 and H3K9me3 did not appear to translate into profound
changes in HP1α, there still exists the possibility that the other two isoforms of HP1 may be
affected. Heterochromatin protein 1 beta (HP1β) would be an interesting protein to study as part
of a future project. HP1β is also localized to constitutive heterochromatin8 and thus, may be
affected by changes in H3K9me3. Although miR-152-3p regulates SETDB1 and affects histone
methylation, there is currently no known effect on HP1α recruitment or heterochromatin
formation.
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CHAPTER 6
FUTURE DIRECTIONS AND PRELIMINARY STUDIES

There are two major areas of focus for which we have performed some preliminary
studies. This section is divided into two parts, I and II, to reflect each of these areas of research.
Part I unites existing research on miR-152-3p targeting of DNMT1 with the body of work
presented thus far. In it, a potential feedback loop between regulation for DNMT1 and SETDB1
is described. In Part II, we propose a potential application for miR-152-3p targeting of SETDB1.
We set forth a case for manipulation of miR-152-3p as a means of facilitating hepatocyte
differentiation. Though we cannot presently draw any conclusions from the preliminary data
presented, we anticipate pursuing both of these areas in the future.
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I. The Potential Role of miR-152-3p as a Molecular Switch between Histone and DNA
Methylation

Background

DNA Methylation and DNA Methyltransferase 1 (DNMT1)
DNA methylation is important for proper epigenetic gene regulation. Dysregulation of
methylation has been linked to diseases such as cancer, Rett syndrome, ATR-X syndrome, and
diabetes60. DNA methyltransferases are a category of enzymes which methylate cytosine
nucleotides in DNA. Like SETDB1, they receive their methyl group from the methyl donor,
SAM61. There are two types of DNA methyltransferases, de novo and maintenance. DNA
methyltransferases 3A and 3B are both de novo methyltransferases, meaning they can add new
methyl groups to cytosine. De novo methyltransferases are active largely during early
development. DNA methyltransferase 1 (DNMT1) is a methylation maintenance enzyme and as
such, functions to preserve methylation patterns after DNA replication.
MiR-152 has a well-established down-regulatory effect on DNMT1. According to Huang,
et. al., transfection of HepG2 cells with miR-152 mimic reduces DNMT1 protein and anti-miR152 treatment increases DNMT1 protein56. These results are supported by Ji, et. al. who also
found that 16HBE (normal human bronchial epithelial) and HEK293T (human embryonic
kidney) cells treated with miR-152 mimic reduce DNMT1 protein levels and that miR-152
targets the 3’UTR of DNMT162. Additionally, Wang, et. al. found treatment of dairy cow
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mammary epithelial cells (DCMEC) with anti-miR-152 results in increased DNMT1 protein
relative to miR-152 treated DCMEC, although protein levels appear to be less than the control
cells. This group concludes that DNMT1 is downregulated by miR-152 via 3’UTR targeting,
which they studied using a luciferase reporter assay63. Thus, miR-152, the miRNA we show upregulates a histone methyltransferase, also down-regulates a DNA methyltransferase.
The idea that DNA methylation and histone methylation are connected is not novel.
Researchers have found that DIM-5, an H3K9me3 KMT, is required for DNA methylation in N.
crassa, a type of filamentous fungi64. With the H3K9me3 mark in place, HP1 is recruited50. The
CSD of HP1 interacts with DIM-2, a DNA cytosine methyltransferase65. Interestingly, DNA
methylation is abolished when the gene encoding HP1, hpo, is knocked out66. This molecular
pathway provides just one example of the related mechanisms between DNA methylation and
histone methylation.

Introduction

The proper maintenance of histone methylation and DNA methylation is crucial for
normal cell function. Dysregulation of methylation can affect development and cause disease.
Cancer is one such example where the epigenetic status of cells is disrupted60, 67, 68. In fact, DNA
promoter hypermethylation resulting in the silencing of miRNA genes is increasingly being
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understood as a hallmark of cancer69, 70. MiRNA profiling of tumors and cancer cell lines
suggests that miRNA levels are also dysregulated in cancer23. Yet, the literature remains scant on
how, precisely, hypermethylation of a miRNA gene promoter impacts the role of that miRNA
and the functioning of its targets.
MiRNA-152 has a well-established role in binding to and repressing DNMT1, a
maintenance DNA methyltransferase56, 62, 63. Recent work published by Sengupta, et. al.
identifies a feedback loop between miR-152 and DNMT1, wherein DNMT1 downregulates miR152 and miR-152 inhibits DNMT171. When considering that the promoter for COPZ2, the
precursor gene of which miR-152 is processed from, is hypermethylated11, a possible regulatory
mechanism involving miR-152, DNMT1, SETDB1, and H3K9me3 begins to emerge. By
applying the DNMT1/miR-152 feedback loop to the targeting and regulation of SETDB1, a new
mechanism emerges relating DNA methylation to histone methylation.
According to the UCSC Genome Browser, miR-152 is processed from the first intron in
the COPZ2 gene. 40 base pairs of the miR-152 transcript and CpG island (CpGi) 56 overlap72
(Figure 6I.1). There are three sites which can be methylated in this overlapping 40 base pair
region. Tsuruta, et. al. noted that methylation at this CpG correlates to decreased levels of miR152 and COPZ2 transcript69. Additionally, within the miR-152 gene lies a CpG island which has
been found to be heavily methylated in ovarian cancer69. We propose the same would be true in
HepG2 cells. We predict that DNMT1 methylates at this particular CpG site, as alluded to in the
work by Sengupta, et. al.71. The literature fails to connect methylation at the CpG island within
miR-152 and global DNA methylation (GDM) to DNMT1 and SETDB1 regulation.
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We hypothesize miR-152 downregulation by DNMT1 increases GDM and promoter
methylation for COPZ2, while decreasing SETDB1 protein, which thereby decreases H3K9me3
and causes gene silencing. Thus, we predict that gene silencing is achieved by two means
resulting from miR-152 suppression by DNMT1: increased GDM and increased histone
methylation. This work would demonstrate for the first time that a miRNA can act as a molecular
switch between histone and DNA methylation.

A.
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B.

Figure 6I.1 Locations of COPZ2, miR-152, and CpGi 56. (A) The COPZ2 gene
body ± 500 base pairs is drawn relative to the locations for CpGi 56 and the miR152 gene. (B) Methylation sites on CpGi 56 are shown in relation to miR-152 and
COPZ2. Diagrams prepared by Heather White, 2017.

Methods

Cell Culture Conditions and Transfection
HepG2 and IMR-91 cells were transfected twice in order to allow sufficient time for cells
to respond to treatment with changes in methylation status. On day 1, cells were passaged and
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plated at 5 x 105 cells per well of a 6-well dish then transfected as described in Chapter 2 with 5
µL inhibitor, 5 µL water, or 0.5 µL mimic in 500 µL serum-free media with 10 µL HiPerFect
transfection reagent. Cells were grown for 24 hours and then 1/4 of cells were passaged into a
new well. These cells were treated again on day 2 with the same quantities of reagents. Cells
were grown for 48 hours, and then collected on day 4. Treatments were done in triplicate. Cells
were washed in DPBS before samples were split in half to have two sets of samples, one for
preparing RNA from and the other for preparing gDNA from.

Sample Preparation for Bisulfite Sequencing and LC/MS
Phenol/chloroform extraction was used to collect genomic DNA (gDNA). For LC/MS, 1
µg DNA was hydrolyzed with DNA Degradase Plus (Zymo, E2020) according to the
manufacturer’s protocol. Briefly, sample was hydrolyzed at 37C for at least 2 hours and then
inactivated at 70C for 20 minutes. Samples were equilibrated to room temperature, quickly
centrifuged, and added to 175 µL of 0.1% formic acid to generate a final concentration of 5
ng/µL.

Bisulfite Sequencing
Samples designated for promoter methylation analysis were split in half in order to
bisulfite convert one set, while keeping the other set unconverted. Both sets underwent the same
basic work flow. First, gDNA samples were PCR amplified for the region of interest. Next, the
insert (either bisulfite converted or unconverted) was cloned into a lacZ reporter vector and
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DH5α cells were transformed. White colonies were picked, cultured over night for mini preps,
and then DNA was isolated, sequenced, and analyzed. For bisulfite conversion to take place, we
used the EZ DNA Methylation Kit from Zymo (catalog #D5001). Unconverted samples were
PCR amplified using Q5 High Fidelity Master Mix (NEB, #M0492). The samples then
underwent Taq addition of 3’A (NEB #M0273) in order to make them compatible with TOPO
TA Cloning (Invitrogen, #K4520-01).
The primers used to generate the region of interest are shown in Table 6I.1 and maps are
provided in Figures 6I.2 and 6I.3 graphically showing where the primers bind. Primers were
designed and maps were prepared by Heather White (2016).

Primer
Abbreviation
FWURG6

RVURG6

FWBSRG1

RVBSRG1

FWBSRG2

RVBSRG2

Primer Sequence (5’ 3’)

Primer Description
Unconverted DNA forward
region 6
Unconverted DNA reverse
region 6
Bisulfite Converted DNA
forward region 1
Bisulfite Converted DNA
reverse region 1
Bisulfite Converted DNA
forward region 2
Bisulfite Converted DNA
reverse region 2

Product Size
(base pairs)

CATGCACTGACTGCTCCAGA
576
CTGGCCACGTCCGCA
GTTAAGGAGGAGAGAGGGAGAGGA
GAAGTGGG
TCTAAATTAACTACTCCCCCTAACC

400

CTACTC
GGGTAGGGATAGAGTAGGGTTAGG
GGGAGTAG
AAAATCCTTCCRAACCCAAATTCTA

466

TCATACAC

Table 6I.1 Primers used to generate PCR products for bisulfite converted and
unconverted DNA. The names of primers, a brief description of the areas they
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span, the sequences are provided. The size of the final product resulting when
primer pairs are used together is also shown.

Figure 6I.2 Graphical representation of the primer recognition sites
(unconverted DNA). The primer recognition sites within the COPZ2 gene to PCR
amplify unconverted DNA are shown. UC FP denotes the unconverted forward
primer, and UC RP denotes the unconverted reverse primer.

Figure 6I.3 Graphical representation of the primer recognition sites (bisulfite
converted DNA). The primer recognition sites within the COPZ2 gene to PCR
amplify bisulfite converted DNA are shown. FW and RV stand for forward and
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reverse, respectively. BSRG is an acronym for bisulfite region, to indicate the
region which will be bisulfite converted.

qPCR for COPZ2
Total RNA was collected using TRIzol Reagent according to the protocol provided.
Following resuspension, RNA was quantified and analyzed for purity with a nanodrop. BioRad’s
iScript kit was used to generate 1 µg cDNA/sample. 10 ng sample and the TaqMan system were
used for qPCR, which was run in triplicate in an Applied Biosystems 7500 machine. Technical
replicate CT values were averaged for COPZ2 and β-ACTIN (βACT). βACT values were
subtracted from COPZ2 to generate ΔCT. ΔΔCT was found by subtracting the water-treated ΔCT
from other sample ΔCT values. This was done for each water-treated ΔCT replicate (i.e. anti-miR152-3p treated replicate #1 ΔCT – water-treated replicate #1 ΔCT, anti-miR-152-3p treated
replicate #1 ΔCT – water-treated replicate #2 ΔCT, anti-miR-152-3p treated replicate #1 ΔCT –
water-treated replicate #3 ΔCT, etc.). Fold change was then calculated as 2-(avgΔCT) for each
sample. Significance was determined using a 1-way ANOVA with raw CT values to asses if there
were significant differences among biological replicates.
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Preliminary Data

qPCR for COPZ2
COPZ2 expression increased as compared to water treated HepG2 cells 12 hours
following anti-miR-152-3p or miR-152-3p mimic treatment (Figure 6I.4). These samples were
the same ones used to obtain SETDB1 expression data in Chapter 2. However, even when cells
were transfected twice, there was no significant difference between the treatment conditions in
HepG2 cells.

Figure 6I.4 COPZ2 expression in HepG2 cells. Cells were treated with antimiR-152-3p and miR-152-3p mimic. Fold change was normalized to both β actin
expression and COPZ2 expression in water-treated cells. There was no significant
difference (p > 0.05) between COPZ2 fold change in anti-miR-152-3p and miR152-3p mimic treated HepG2 cells.
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As with HepG2 cells, COPZ2 expression increased regardless of treatment as compared
to control conditions in IMR-91 cells transfected for 12 hours (Figure 6I.5). Oddly, results could
not be analyzed for IMR-91 samples transfected twice as there appears to be an unanticipated
effect on our chosen normalization control, β-actin (Table 6I.2).

Figure 6I.5 COPZ2 expression in IMR-91 cells. Cells were treated with antimiR-152-3p and miR-152-3p mimic for 12 hours. Fold change was normalized to
both β actin expression and COPZ2 expression in water-treated cells. There was
no significant difference (p > 0.05) between COPZ2 fold change in anti-miR-1523p and miR-152-3p mimic treated IMR-91 cells.
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Beta Actin
Treatment
Bio.
Condition Replicate

1
20
dH

2
3
1

an
m

ti-

2

iR

3
1
ic

im

m

2
3

COPZ2

Cт

Avg Cт

Cт Std
Dev

32.86
32.52
34.03
30.32
30.04
30.59
33.13
35.22
33.75
36.79
35.06
37.28
U
U
U
U
U
U
U
U
U
37.10
34.66
36.53
U
35.58
U

33.13

0.65

30.31

0.23

34.03

0.88

36.38

0.95

U

U

U

U

U

U

36.10

1.04

35.58

0.00

Cт

Avg Cт

Cт Std
Dev

32.50
31.90
32.43
30.09
30.28
29.48
31.71
31.26
31.72
32.88
32.87
32.60
35.19
33.91
33.60
35.53
36.20
U
34.28
34.60
33.88
33.39
33.42
32.80
37.13
36.58
36.58

32.28

0.27

29.95

0.34

31.56

0.21

32.78

0.13

34.24

0.69

35.87

0.33

34.25

0.29

33.20

0.29

36.76

0.26

Table 6I.2 Cycle threshold (CT) values for IMR-91 cells transfected twice. CT
values were undetermined (U) for the majority of IMR-91 cells transfected with
anti-miR-152-3p or miR-152-3p mimic.

Bisulfite Sequencing
Sequence alignments for preliminary data can be found in Appendix II: Supplementary
Data.
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II. miR-152-3p in Hepatocyte Differentiation

Introduction

MiRNAs can be studied in the contexts of development and differentiation. By
determining which miRNAs are expressed during the different stages of these processes, we can
begin to modulate them and drive pluripotency, lineage specification, and cell fate for
therapeutic purposes. For example, miR-145 targets the 3’UTRs and down-regulates key
pluripotency genes, OCT4, SOX2, and KLF4. MiR-145 thereby suppresses pluripotency in
human embryonic stem cells (hESCs). One might then expect inhibition of miR-145 would
induce pluripotency. Yet, Xu, et. al. found differentiation was actually impaired, despite elevated
levels of OCT4, SOX2, and KLF473. Thus, it is important to go beyond simply determining
which miRNAs are expressed during stages of development or differentiation and to actually
study the effects of individual miRNAs.
MiR-152 may have a role in hepatocyte differentiation. According to work by Kim, et.al.,
miR-152 was found to be among the top ten miRNAs which increased in expression during the
transition from definitive endoderm to hepatocyte cell during the differentiation of human
embryonic stem cells (Figure 6II.1)19. This work was performed using hESCs and a 23 day
differentiation protocol. However, the group did not look at expression of these miRNAs during
the intermediate stages of hepatic lineage induction or hepatoblast formation. Nor did they
conduct studies on the necessity or functions of any of these miRNAs. However, other research
groups have examined some of the miRNAs identified to change in expression during these
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stages. For example, overexpression of miR-122 has been found to promote hepatic
differentiation74. Likewise, miR-152 may also be involved in hepatocyte differentiation.

Figure 6II.1 MicroRNAs increasing in expression. This graph was adapted
from Kim, et.al.19 and shows the top 10 miRNAs which increase in expression
during differentiation from definitive endoderm (DE) to hepatocytes (HEP).

MiR-152-3p has three relevant categories of targets (Table S.1) which may implicate it in
hepatocyte differentiation. The first category is methylation and includes SETDB1 and DNMT1.
As established by the work presented in Chapters 2 through 5, miR-152-3p enhances SETDB1
activity. Others have shown that miR-152-3p also down-regulates DNMT156, 62, 63. This feedback
loop may facilitate the expression of hepatic genes, while silencing stem cell genes. One way to
study this would be to complete a qPCR analysis of LDLr, CYP genes, and AFP/ALB on anti-
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miR-152-3p, miR-152-3p mimic, and control (water-treated) cells throughout the stages of
differentiation. If there is a significant difference among the treatment and control groups for any
of those genes, further studies can be done to confirm that it is due to miR-152-3p effects on
methylation.
The second relevant category of miR-152-3p targets is generally involved in
differentiation. This includes FGF2, KLF4, and WNT1. The final category of miR-152-3p targets
is insulin-signaling related. Insulin-signaling may be required for in vitro hepatocyte
differentiation (Winfried Kruger, 2013). Thus, miR-152-3p targeting of IGF1R and IRS1 may be
relevant. Finally, the possibility exists that multiple targets may be relevant, should miR-152-3p
be found necessary for hepatocyte differentiation. A recent study published by Fráguas, et. al.
showed miR-29 targeting of DNA demethylation enzymes and wnt signaling molecules impairs
early reprogramming75.
With so many possible avenues for miR-152-3p involvement in hepatocyte
differentiation, the central questions are:
1. Does miR-152-3p affect the progress of cells from definitive endoderm to
hepatocyte?
2. If miR-152-3p affects the progress of cells from definitive endoderm to hepatocyte,
via which target(s) does this occur?
3. Can modulation of miR-152-3p positively contribute to hepatocyte differentiation?
By addressing these questions, one may be able to improve the quality of HLCs, shorten
differentiation time, and determine the necessity and function of miR-152 in stem cell
differentiation to hepatocytes.
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There are several steps that must be taken prior to embarking on any experiments that
address the specific questions presented here. First, if an iPSC model is to be used, the lines must
be validated for pluripotency. Next, the differentiation protocol should be qualified. The
hepatocyte differentiation protocol employed in our laboratory is summarized in Figure 6II.2.
Finally, a protocol by which adherent cells growing in multiple layers can be efficiently
transfected with miRNA inhibitors and mimics should be developed. Once these challenges are
overcome, a simple first experiment is to profile miR-152 expression across all 4 stages of
differentiation. Next, mRNA and protein expression analysis should be done for the 7 relevant
targets described. Finally, miR-152-3p inhibitor and mimic can be introduced and the effects can
be studied. Appropriate follow-up experiments can be designed to address any new questions
that emerge.

Figure 6II.2 Hepatocyte differentiation protocol. Our research group’s
hepatocyte differentiation protocol is summarized and phase/contrast images of
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cells at each stage are shown. There are 4 stages of hepatocyte differentiation.
Stage progression depends on the composition of growth media. Cell morphology
begins to resemble hepatocytes at Stage 2.

The data presented represents preliminary findings and must be followed up before any
conclusions regarding the role of miR-152 in hepatocyte differentiation can be made.

Methods

iPSC Culture Conditions
Induced pluripotent stem cell line SS1.4 was generated from human fibroblast cell line
IMR-91 (Coriell, #I91S-04). Cells were grown at 37C in a 5% CO2 incubator under sterile
conditions on hESC-qualified Matrigel (Corning #354277) in mTeSR1 (Stem Cell technologies
#05857). Media was changed daily and cells were mechanically passaged every 4-6 days prior to
hepatocyte differentiation.
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Hepatocyte Differentiation
On day 0, SS1.4 cells were dissociated using Accutase and seeded at 100,000 cells per
cm2 in mTESR1 supplemented with 1x Thioazovivin. On day 1, media is changed to Stage 1.1
(S1.1) media consisting of RPMI 1640 with 1 x B27, 1 x NEAA, 100 ng/mL Activin A (Prospec
Inc.), 20 ng/mL FGF2 (R&D Systems), and 10 ng/mL BMP4 (Prospec Inc.). S1.1 media is
replaced with fresh S1.1 media on day 2. On days 3-5, media is changed daily with S1.2 media.
The S1.2 media composition is RPMI 1640 with 1 x B27, 1 x NEAA, and 100 ng/mL Activin A.
On day 6, S1.2 media is replaced with HCM.S2. The base media, HCM (Promocell), is
supplemented with Transferrin, Ascorbate, Hydrocrtisone, and BSA. 5 µg/mL Insulin, 20 ng/mL
BMP4, and 10 ng/mL FGF2 are added to create HCM.S2, which is changed daily for 5 days. On
day 11, HCM.S2 is replaced with HCM.S3 (supplemented HCM with 20 ng/mL Insulin, 20
ng/mL HGF). Media is again changed daily for 5 days. On day 16, media is changed to HCM.S4,
which consists of supplemented HCM with 20 ng/mL Insulin, 10 ng/mL OSM (dissolved in
0.3% BSA/PBS) and 0.1 µM Dexamethsone. Media is changed daily for 5 days. This protocol
was developed by Winfried Kruger (2013).

qPCR for miR-152
RNA was isolated from cells at each stage of differentiation using miRNeasy Mini Kit
(Qiagen, # 217004). cDNA was generated using the miScript PCR Starter Kit (Qiagen,
#218193). miScript Primer Assays for RNU6 and miR-152 were used in SYBR green-based
qPCR according to kit instructions on a Bio-Rad CFX-96 Real-Time System.
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Preliminary Data

HLC Validation
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Figure 6II.3 Fold induction of HLC genes. Fold induction was calculated
according to the data analysis method published by Livak, et. al.76. We observed
an incomplete progression to HLC. Gene expressions were normalized to β-actin.
Differentiation to HLC was performed according to a protocol written by
Winfried Kruger (2013).

90

qPCR for miR-152

Figure 6II.4 miR-152 expression during HLC induction from iPSC.
Expression was calculated as fold change from Day 0 iPSC line SS1.4 derived
from IMR-91. MiR-152 levels showed a positive trend during Stage 4, though
significance could not be determined at Stage 4 due to sample size. Two values
were obtained for fold change at Stage 4, they were 29.7 and 131.2. The fold
change of 29.7 was chosen as the representative value for depiction, though both
values illustrated the increase in miR-152 expression seen at Stage 4.
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APPENDIX I
PROTOCOLS

Transfection of HepG2 or IMR-91 Cells with miRNA Mimic, miRNA Inhibitor, or Water
in a 10 cm Dish

(Protocol modified from Qiagen, last updated 09/2013)
Cell seeding and transfection are performed on the same day. Allow 1-2 hours from startto-finish for preparing the hood, counting cells, seeding cells, and transfecting cells, depending
on the number of plates being used. For IMR-91 cells, coat plates in 0.1% gelatin for 30 minutes
at 37C prior to cell seeding. During the 30 minute coating step, or 30 minutes prior to initiating
protocol, set up the cell culture hood.
Begin by warming media (IMR-91: DMEM with 4.5 g/L glucose, 100X GlutaMax, and
10% FBS; HepG2: DMEM with 1.0 g/L glucose and 10% FBS) at 37C in bead or water bath,
equilibrating 0.05% Trypsin-EDTA (Life Technologies, #25300054) and Dulbecco’s PBS (Life
Technologies, #14190) to room temperature, and obtaining fresh ice. Prepare serum-free media
(IMR-91: DMEM with 4.5 g/L glucose and 100X GlutaMax; HepG2: DMEM with 1.0 g/L
glucose). Label 15 mL tubes for preparing transfection complexes in. Label treatment conditions
on the 10 cm dishes for HepG2 cells at this time and for IMR-91 cells when the 30 minute
coating step is complete. Label 40 mL Falcon tubes for passaging cells. Sanitize and place

99

necessary tube stands, 5 mL and 10 mL serological pipettes, pipette aids, micro pipette tips,
micro pipettors, etc. in the hood.
Prior to initiating protocol, passage and count cells.
1. Seed 2.4 x 106 HepG2 cells or 1.26 x 106 IMR-91 cells (under passage #20) in 8.452 mL
media in transfecting with mimic or 8.43 mL media if transfecting with water or anti-miR per
well of a 10 cm dish.
2. Incubate cells until transfection complexes are formed (after step 4 is complete) at 37C with
5% CO2.
3. In the labeled 15 mL tubes, dilute 2.5 µL mimic, 25 µL anti-miR, or 25 µL water in 1.5 mL
of the appropriate serum-free media for each cell line. Add 45 µL HiPerFect Transfection
Reagent (Qiagen, #301705) per tube. These quantities are fixed per single 10 cm dish. For
replicates, multiple these values (ex: For 2 x HepG2 + mimic plates, use: 5 µL mimic, 3 mL
DMEM + 1.0 g/L glucose, and 90 µL HiPerFect transfection reagent).
4. Vortex 15 mL tubes containing treatment, media, and transfection reagent briefly to mix.
Quick spin centrifuge if need. Incubate at room temperature for 5-10 minutes to form
transfection complexes.
5. Add the complexes drop-wise onto cells and swirl the plate to ensure even distribution of
reagents and cells.
6. Incubate plates at 37C with 5% CO2 until cells are ready to collect.
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InFusion Cloning Protocol for Preparing Reporter Vector + SETDB1 3’UTR
1. Prepare linearized vector using restriction enzyme digest (RED) and check background.
a. RED pE1330: 0.5 µL pE1330 DNA (1000ng, Promega, #e1330) + 1 µL SacI-HF
(NEB, R3156S) + 1 µL XbaI (NEB, R0145T) + 5 µL NEBuffer + 42.5 µL dH2O 
37C overnight  65C for 20 minutes  add 10 µL sample buffer and gel purify on
1% agarose gel run at 90V with Macherey Nagel gel purification kit (#740609)
provided with InFusion Cloning kit. Nanodrop = 948ng/20 µL.
b. Negative control: transformed Stellar Competent Cells with 2.37 µL linearized
e1330 (5 ng) according to the Stellar Competent Cells protocol #PT5055-2 provided
through Clontech:
http://www.clontech.com/US/Products/Cloning_and_Competent_Cells/Competent_C
ells/ibcGetAttachment.jsp?cItemId=17313&fileId=5877577&sitex=10020:22372:US
Plated 100 µL on LB+amp (A). Pelleted remaining cells at 6000 rpm for 5 min then
resuspended in 100 µL and plated on LB+amp (B). After incubation at 37C
overnight, saw 3 colonies on A and 2 colonies on B.
2. Design PCR primers to amplify the SETDB1 3’UTR using the InFusion Primer Design
program or by following the guidelines provided in the manual.
a. Entered pE1330 vector sequence, selected XbaI and SacI RE, did not preserve
restriction site (doing so creates primers that are > 5C apart), get fragmen.t
b. Resulted in 14 bases excised and 7336bp linearized vector, inserting fragment based
off Genome Browser’s SETDB1 3’UTR DNA sequence. Gave:
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*The Tm is incorrect due to glitch in programing. Actual melting temperatures are
55.8C for FWP and 44.6C for RVP, according to Integrated DNA Technologies Tm
Calculator.
3. PCR amplify the SETDB1 3’UTR using CloneAmp HiFi PCR Premix and HepG2 cDNA
a. Convert HepG2 RNA to cDNA using the iScript cDNA Synthesis Kit (BioRad,
#1708841) by combining the following in a PCR tube and running the Thermocycler
on the iScript setting:
4 µL 5x iScript Reaction Mix
2.69 µL dH20
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2.31 µL RNA template (1 µg RNA)
1 µL iScript Reverse Transcriptase (add last)
b. In order to generate insert, follow the protocol provided with CloneAmp HiFi PCR
Premix according to Option A (98C for 10 seconds, 55C for 5 or 15 seconds, 72C
for 5 seconds/kb = 5 seconds total). Prepare the following in a PCR tube and run on
CloneAmp setting in the Thermocycler:
12.5 µL PCR Pre-mix
1 µL each of 5 pmol FWP/RVP
1.8 µL of template (90 ng)
8.7 µL dH20
c. Confirm PCR product size on 1% agarose gel at 90V
4. Either purify PCR product or treat with Cloning Enhancer and follow with appropriate
Enzyme Premix treatment protocol (see p 9-10 of User Manual). Conduct positive control in
parallel using provided 2 kb control insert.
5. Transform Stellar Competent Cells with Reaction Mixture/Control Insert according to
protocol provided (see link under 1b).
6. Pick colonies, create overnights, make mini preps and confirm presence of insert through
diagnostic digests (PmeI/DraI + NotI, for example). Sequence sample that looks promising.
7. Maxi prep pE1330+SETDB1 3’ UTR (here on called pE1330S3U)/pE1330 (to be used as
positive control since no insert is present)
8. Transfect HepG2 with pE1330S3U/pE1330 using Lipofectamine 2000 (optimization will be
required – follow protocol and analyze cells at 24, 48, and 72 hours post-transfection) to
determine experimental parameters for all transfections. Conduct in 6 replicates.
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Lipofectamine 2000 Transfection Protocol for HepG2 and IMR-91 Cells
1. Day 0. Plate 10,000 cells/well of a 96-well white wall plate (Fisher Scientific, #08-771-26) in
75 µL growth media. Plate 6 replicates per sample, remembering to include extra for positive
and negative controls as well as a blank for when the plate is read.
2. Day 1. Prepare reagents for transfection as described:
A. Combine 1200 ng DNA + Opti-MEM to 60 µL.
Name

µL DNA

µL Opti-MEM

pE1330

0.60

59.4

pE1330S3U

14.88

45.1

pE1330S3Upbs1-

8.00

52.0

pE1330S3Upbs2-

2.24

57.8

pE1330S3Upbs3-

2.14

57.9

These DNA samples are stored at -20C in the Cell Culture room.
B. Combine 300 µL Opti-MEM + 24 µL Lipofectamine 2000
3. For sample wells, combine equal parts (60 µL A + 60 µL B) of diluted DNA with diluted
Lipofectamine 2000 in a fresh microcentrifuge tube. For control wells, combine 120 µL OptiMEM + 4.8 µL Lipofectamine 2000 in a fresh microcentrifuge tube. Incubate tubes at room
temperature for 5 minutes. Transfect cells with 10 µL solution per well (sample: 100 ng
DNA/well). There will be enough solution to transfect 6 x HepG2 sample wells, 6 x IMR-91
sample wells, 6 x HepG2 control wells, and 6 x IMR-91 control wells.
4. Day 2. Change media to a volume of 75 µL/well and begin the Dual Glo Luciferase Assay
System Protocol.
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Dual Glo Luciferase Assay System Protocol and Data Analysis
(Modified from Promega, #E2920, last updated 09/2015)
1. Prepare reagents according to manufacturer’s protocol
2. Equilibrate reagents and cells to room temperature
3. Add 75 µL/well of Dual-Glo Reagent then wait 10 minutes to allow cells to lyse
4. Measure firefly luminescence on the LMAX II luminometer
5. Add 75 µL/well of Dual-Glo Stop & Glo Reagent and wait 10 minutes before measuring
Renilla luminescence
6. Analyze data accordingly:
A. Subtract Blank well luminescence from raw luciferase luminescence values
LUCraw – BLANK = LUC
B. Subtract Blank well luminescence from raw Renilla luminescence values
RENraw – BLANK = REN
C. Create a luciferase luminescence to Renilla luminescence ratio by dividing the
background subtracted values
LUC/REN = luciferase/Renilla ratio
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APPENDIX II
SUPPLEMENTARY DATA
Confirmed hsa-miR-152-3p Targets
Target
ADAM17
B4GALT5
C18orf25
CCKBR
CCND1
CD151

Description of Gene/Protein
Disintegrin involved in autoimmune diseases
Glycoprotein; Beta-1,4-galactosyltransferase 5
Protein uncharacterized
Gastrin and cholecystokinin receptor
Cyclin D 1
Cell surface glycoprotein, member of transmembrane 4 superfamily
proteins
CLOCK Circadian Locomotor Output Cycles Kaput
CSF1
Macrophage colony stimulating factor; cytokine
DNMT1 Maintenance DNA methyltransferase
EMP1
Epithelial Membrane Protein 1; localized to tight junctions
FGF2
Fibroblast growth factor 2
FGFR3
Fibroblast growth factor receptor 3; promotes HCC metastasis
HLA-G
Histocompatibility antigen
IGF1R
Insulin growth factor
IRS1
Insulin receptor substrate
ITGA5
Fibronectin and fibrinogen receptor; integrin alpha chain family
KIAA0232 Nuclear phosphoserine protein
KLF4
Transcription factor; regulates cell proliferation, differentiation,
apoptosis and can be used for reprogramming somatic cells
KRAS
GTPase
MAFB
Transcriptional activator or repressor in lineage-specific
hematopoiesis regulation
MOSPD1 Implicated in mesenchymal and epithelial cell development
MXD1
MAX dimerization protein 1; forms a DNA-binding protein
complex, MAD-MAX
PHACTR2 Phosphatase and Actin Regulator 2; involved in platelet activation,
signaling and aggregation
RMND5A Required For Meiotic Nuclear Division 5 Homolog A
SETDB1 Histone methyltransferase
STRADB Pseudokinase involved in the activation of serine/threonine kinase
11; involved in cell polarity and metabolism
TACC3
Motor spindle protein
TGFA
Transforming growth factor; epidermal growth factor
WNT1
Wnt-signaling, oncogenesis, development and differentiation
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Table S.1 List of miR-152-3p targets. The targets listed here all have strong
evidence supporting their interactions with miR-152-3p. Strong evidence is
defined as originating from a reporter assay, western blot, or qPCR24.
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Lipofectamine 2000 Transfection Optimization Data

Figure S.1 Transfection parameter optimization results. In order to determine
what quantity of transfection reagent to use, HepG2 cells were transfected with
the specified quantities of Lipofectamine 2000 using either empty vector
(Promega, #e1330) or vector + SETDB1 3’UTR and luminescence was
calculated. The 2 µL quantity was chosen for subsequent experiments due to the
consistent, robust observed luciferase/Renilla ratio.
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Inverted Immunofluorescence Images
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Figure S.4 HP1α visualization under inverted microscopy. Representative 40x
magnification inverted microscopy images of HP1α staining in HepG2 and IMR91 cells treated with water, anti-miR-152-3p, and miR-152-3p with 1.8 second
exposure for FITC. Cell staining and image collection performed by Madeline
Dorso (2016).
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Key
TRS 1

TRS 2

TRS 3

Plasmid Sequence

SETDB1 3’UTR Sequence

Base Substitution

- - - - - - - - - - - - Deletion

Sequencing Results for Vector + SETDB1 3’UTR (pE1330S3U)
Forward Sequence for pE1330S3U
5’-CGTGATTCTAGTTGTTTAAACGAGGAAGCCTTCTTCCCAACCCTTCTTGAACTGT
CGTTTCCTCAGGAACTGGGTCTTCCTGATTGTTGAACCCTGACCCGAAGTCTCTGG
GCTAGCTACTCCCCCCAGCTCCTAGTTGATAGAAATGGGGGTTCTGGACCAGATGAT
CCCTTCCAATGTGGTGCTAGCAGGCAGGATCCCTTCTCCACCTCCAAAGGCCCTAA
AGGGTGGGGAGAGATCACCACTCTAACCTCGGCCTGACATCCCTCCCATCCCATATT
TGTCCAAGTGTTCCTGCTTCTAACAGACTTTGTTCTTAGAATGGAGCCTGTGTATCTA
CTATCTCCAGTTTGTATTATTTCTTGAAAGTCTTTTAACAATATGATAAAACTAAGAT
TGTGCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGA
AAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGG
GGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACA
ACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTA
TTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTT
ATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTAC
AAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGG
TATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGC
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ACCATGGCCTGAAATAACCTCTGAAAGAGGGAACTTGGTTAGGTACCTTTCTGAGGC
GGAAGAACCAGCTGTGGGATGTGTGTCAGTTTAGGGTGTGGGAAAGTCCCCAGGCT
CCCCAGCAGCAGAAGTATGCCAAAGCATGCATCTCATAGTCAGCACCCAAGGTGTG
CAAGTCCCCCAGGCTC-3’

Reverse Sequence for pE1330S3U
5’-TTCCCTGAGTCGATCTAGCACAATCTTAGTTTTATCTATTGTTAAAAGACTTTCA
AGAAATAATACAAACTGGAGATAGTAGATACACAGGCTCCATTCTAAGAACAAAGT
CTGTTAGAAGCAGGAACACTTGGACAAATATGGGATGGGAGGGATGTCAGGCCGAG
GTTAGAGTGGTGATCTCTCCCCACCCTTTAGGGCCTTTGGAGGTGGAGAAGGGATCC
TGCCTGCTAGCACCACATTGGAAGGGATCATCTGGTCCAGAACCCCCATTTCTATC
AACTAGGAGCTGGGGGGAGTAGCTAGCCCAGAGACTTCGGGTCAGGGTTCAACAAT
CAGGAAGACCCAGTTCCTGAGGAAACGACAGTTCAAGAAGGGTTGGGAAGAAG
GCTGTCCTCGTTTAAACAACTAGAATTACACGGCGATCTTGCCGCCCTTCTTGGCCTT
AATGAGAATCTCGCGGATCTTGCGGGCGTCCAACTTGCCGGTCAGTCCTTTAGGCAC
CTCGTCCACGAACACAACACCACCGCGCAGCTTCTTGGCGGTTGTAACCTGGCTGGC
CACATAGTCCACGATCTCCTTCTCGGTCATGGTTTTACCGTGTTCCAGCACGACGACT
GCGGCGGGCAGCTCGCCGGCATCGTCGTCGGGCAGGCCGGCGACCCCGGCGTCGAA
GATGTTGGGGTGTTGCAGCAGGATGCTCTCCAGTTCGGCTGGCGCTACCTGGTAGCC
CTTGTATTTGATCAGGCTCTTCAGCCGGTCCACGATGAAGAAGTGCTCGTCCTCGTC
CCAGTAGGCGATGTCGCCGCTGTGCAGCCAGCCGTCCTTGTCGATGAGAGCGTTTGT
AGCCTCGGGGTTGTTAACGTAGCCGCTCATGATCATGGGGCCACGGACGCACAGCT
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CGCCGCGCTGGTTCACACCCAGTGTCTTACCCGGTGTCCCAAGTCCACCCACCTTAG
CCTCGAGACGCACCCACCCTTGCCCTACTGCGCCAGGCTTTGTCGTCCCCTTTCGGG
GGGGTGAT-3’
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Sequencing Results for Vector + SETDB1 3’UTR with Target Recognition Sequence 1
Deletion (pE1330S3UTRSΔ1)

Forward Sequence for pE1330S3UTRSΔ1
5’-CCGTGTATTCAGTTGTTTAAACGAGGCAGCCTTCTT- - - - - - - - - - - - - - - - - - - -CGT
TTCCTCAGGAACTGGGTCTTCCTGATTGTTGAACCCTGACCCGAAGTCTCTGGGCT
AGCTACTCCCCCCAGCTCCTAGTTGATAGAAATGGGGGTTCTGGACCAGATGATCC
CTTCCAATGTGGTGCTAGCAGGCAGGATCCCTTCTCCACCTCCAAAGGCCCTAAAG
GGTGGGGAGAGATCACCACTCTAACCTCGGCCTGACATCCCTCCCATCCCATATTTG
TCCAAGTGTTCCTGCTTCTAACAGACTTTGTTCTTAGAATGGAGCCTGTGTATCTACT
ATCTCCAGTTTGTATTATTTCTTGAAAGTCTTTTAACAATATGATAAAACTAAGATTG
TGCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAA
GGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGG
CGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAAC
TAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTT
GTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATG
TTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAA
TGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTAT
TTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCAC
CATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGG
AAAGAACCAGCTGTGGAATGTGTGTCAGTTTAGGGTGTGGAAAAGATCCCCCACGC
TTCCCCAGCAGCAGAAGGTAATTGCAAAAGCATGGCATTCTTCCAATTTAGTTCAGG
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CCAACCCAGGTTGTTGGTAAAGATCCCCCAGGGCTTCCCCCCAGGCATGCAGGAAG
TTATTGGCAAAAGCATGCCATCTTCAATTAGTTCCAGCAACCATTAGTTCCCGGCCC
CCTTTAAACCTTTCCCGGC-3’

Reverse Sequence for pE1330S3UTRSΔ1
5’-CATGCCTGCAGTCGCTCTGCACAATCTTAGTTTTATCTATTGTTAAAAGACTTTCA
GAAATAATACAAACTGGAGATAGTAGATACACAGGCTCCATTCTAAGAACAAAGTC
TGTTAGAAGCAGGAACACTTGGACAAATATGGGATGGGAGGGATGTCAGGCCGAGG
TTAGAGTGGTGATCTCTCCCCACCCTTTAGGGCCTTTGGAGGTGGAGAAGGGATCCT
GCCTGCTAGCACCACATTGGAAGGGATCATCTGGTCCAGAACCCCCATTTCTATCA
ACTAGGAGCTGGGGGGAGTAGCTAGCCCAGAGACTTCGGGTCAGGGTTCAACAATC
AGGAAGACCCAGTTCCTGAGGAAACG- - - - - - - - - - - - - - - - - - - -AAGAAGGCTGTCC
TCGTTTAAACAACTAGAATTACACGGCGATCTTGCCGCCCTTCTTGGCCTTAATGAG
AATCTCGCGGATCTTGCGGGCGTCCAACTTGCCGGTCAGTCCTTTAGGCACCTCGTC
CACGAACACAACACCACCGCGCAGCTTCTTGGCGGTTGTAACCTGGCTGGCCACATA
GTCCACGATCTCCTTCTCGGTCATGGTTTTACCGTGTTCCAGCACGACGACTGCGGC
GGGCAGCTCGCCGGCATCGTCGTCGGGCAGGCCGGCGACCCCGGCGTCGAAGATGT
TGGGGTGTTGCAGCAGGATGCTCTCCAGTTCGGCTGGGGCTACCTGGTAGCCCTTGT
ATTTGATCAGGCTCTTCAGCCGGTCCACGATGAAGAAGTGCTCGTCCTCGTCCCAGT
AGGCGATGTCGCCGCTGTGCAGCCAGCCGTCCTTGTCGATGAGAGCGTTTGTAGCCT
CGGGGTTGTTAACGTAGCCGCTCATGATCATGGGGCCACGGACGCACAGCTCGCCG
CGCTGGTTCACACCCCAGTGTCTTACCCGGTGTCCAAGTCCACCACCTTAGCCTCGA
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AAGAATGGGCACCACCTTTGCCCTACTGCGCCAGGCTTGTCGTCCCCCTTTCGGGGG
GTGATCAGAAATGACGCTTGGTTGTTTCTGTCATGCCGTAGCCTTGGCGATGCCTGG
TAGTGGAAGCGGTTGGCACGGCTCACTACCTCCTGCTGAGCGGCG-3’
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Sequencing Results for Vector + SETDB1 3’UTR with Target Recognition Sequence 2
Deletion (pE1330S3UTRSΔ2)

Forward Sequence for pE1330S3UTRSΔ2
5’-CGTGTATCAGTTGTTTAACGAGGAAGCCTTCTTCCCAACCCTTCTTGAACTGTCC
GTTTCCTCAGGA- - - - - - - - - - - - - - - - - - - TGAACCCTGACCCGAAGTCTCTGGGCTA
GCTACTCCCCCCAGCTCCTAGTTGATAGAAATGGGGGTTCTGGACCAGATGATCCC
TTCCAATGTGGTGCTAGCAGGCAGGATCCCTTCTCCACCTCCAAAGGCCCTAAAGG
GTGGGGAGAGATCACCACTCTAACCTCGGCCTGACATCCCTCCCATCCCATATTTGT
CCAAGTGTTCCTGCTTCTAACAGACTTTGTTCTTAGAATGGAGCCTGTGTATCTACTA
TCTCCAGTTTGTATTATTTCTTGAAAGTCTTTTAACAATATGATAAAACTAAGATTGT
GCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAG
GAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGC
GGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACT
AGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTG
TAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGT
TTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAAT
GTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATT
TTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCACC
ATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAA
AGAACCAGCTGTGGAATGTGTGTCAGTTAGGGGTGTGGAAAGTCCCCAGGCTCCCC
AGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAAACCCAGGTGTGG
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AAAGTCCCCCAGGGCTCCCCCAGCAGGGCAGAAGTATGCAAAGCATGCATCTCAAA
TTTAAGTCAGCACCATAGTCCCCGCCCTAACCTCGCCATCCCGCCCCTACTACGACC
AGTACGTCCAATTCTTCCGG-3’

Reverse Sequence for pE1330S3UTRSΔ2
5’-AAGCCTGCAGTCGATCTAGCACAATCTTAGTTTTATCATATTGTTAAAAGACTTTC
CAAGAAATAATACAAACTGGAGATAGTAGATACACAGGCTCCATTCTAAGAACAAA
GTCTGTTAGAAGCAGGAACACTTGGACAAATATGGGATGGGAGGGATGTCAGGCCG
AGGTTAGAGTGGTGATCTCTCCCCACCCTTTAGGGCCTTTGGAGGTGGAGAAGGGAT
CCTGCCTGCTAGCACCACATTGGAAGGGATCATCTGGTCCAGAACCCCCATTTCTA
TCAACTAGGAGCTGGGGGGAGTAGCTAGCCCAGAGACTTCGGGTCAGGGTTCA- - - - - - - - - - - - - - - - - -TCCTGAGGAAACGACAGTTCAAGAAGGGTTGGGAAGAAGGCT
GTCCTCGTTTAAACAACTAGAATTACACGGCGATCTTGCCGCCCTTCTTGGCCTTAAT
GAGAATCTCGCGGATCTTGCGGGCGTCCAACTTGCCGGTCAGTCCTTTAGGCACCTC
GTCCACGAACACAACACCACCGCGCAGCTTCTTGGCGGTTGTAACCTGGCTGGCCAC
ATAGTCCACGATCTCCTTCTCGGTCATGGTTTTACCGTGTTCCAGCACGACGACTGCG
GCGGGCAGCTCGCCGGCATCGTCGTCGGGCAGGCCGGCGACCCCGGCGTCGAAGAT
GTTGGGGTGTTGCAGCAGGATGCTCTCCAGTTCGGCTGGGGCTACCTGGTAGCCCTT
GTATTTGATCAGGCTCTTCAGCCGGTCCACGATGAAGAAGTGCTCGTCCTCGTCCCA
GTAGGCGATGTCGCCGCTGTGCAGCCAGCCGTCCTTGTCGATGAGAGCGTTTGTAGC
CTCGGGGTTGTTAACGTAGCCGCTCATGATCATGGGGCCACGGACGCACAGCTCGCC
GCGCTGGTTCACACCCAGTGTCTTACCGGTGTCCAAGTCCACCACCTTAGCCTCGAA
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GAAGGCACCACCTTGCCTACTGCGCCAGGCTTGTCGTCCCCTTCGGGGGTGATCAGA
ATGGCGCTGGGTTGTTTCTGTCAGGCCGTAGCCCTGGCGGATGCCCTGGGTAGGTGG
GAAGCGTTTGACCACGGCCTCACCCTACCTACTGCTGGAGCGCCGGCCCCCCGTCGC
TTGCGAATCTCGTGCCAGTGCTAGTCGTACCTGGTCGAATGCAAGAAGACTC-3’
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Sequencing Results for Vector + SETDB1 3’UTR with Target Recognition Sequence 3
Deletion (pE1330S3UTRSΔ3)

Forward Sequence for pE1330S3UTRSΔ3
5’-CCGTGTATCAGTTGTTTAAACGAGAAAGCCTTCTT-CCAACCCTTCTTGAACTGT
CGTTTCCTCAGGAACTGGGTCTTCCTGATTGTTGAACCCTGACCCGAAGTCTCTGG
GCTAGCTACTCCCCCCAGCTCCTAGTTGATAGAAATGGGGGTTCTGGACCAG- - - - - - - - - - - - - - - - - - - -AGCAGGCAGGATCCCTTCTCCACCTCCAAAGGCCCTAAAGGGTG
GGGAGAGATCACCACTCTAACCTCGGCCTGACATCCCTCCCATCCCATATTTGTCCA
AGTGTTCCTGCTTCTAACAGACTTTGTTCTTAGAATGGAGCCTGTGTATCTACTATCT
CCAGTTTGTATTATTTCTTGAAAGTCTTTTAACAATATGATAAAACTAAGATTGTGCT
AGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCC
GCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAA
TGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAC
CATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCA
GGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAATGTG
GTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCT
CCTTACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCACCATGG
CCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAA
CCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCCAGCAG
GCAGAAAGTATGCAAAAGCATGCATCTCAATTAGTCAGCAAACCCAGGTGTGGGAA
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AGTCCCCAGGCTCCCCAAGCAAGCCAGAAGTATGCAAAGCCATGGCATTCCTTCCAT
TTAGTTCAGGCACCAATAGTCCCCGGCCCCCCCT-3’

Reverse Sequence for pE1330S3UTRSΔ3
5’- ATGGCCTGCAGTCGCTCTGCACAATCTTAGTTTTATCTATTGTTAAAAGACTTTTA
AGAAATAATACAAACTGGAGATAGTAGATACACAGGCTCCATTCTAAGAACAAAGT
CTGTTAGAAGCAGGAACACTTGGACAAATATGGGATGGGAGGGATGTCAGGCCGAG
GTTAGAGTGGTGATCTCTCCCCACCCTTTAGGGCCTTTGGAGGTGGAGAAGGGATCC
TGCCTGCTA- - - - - - - - - - - - - - - - - - - - -CTGGTCCAGAACCCCCATTTCTATCAACTAG
GAGCTGGGGGGAGTAGCTAGCCCAGAGACTTCGGGTCAGGGTTCAACAATCAGGA
AGACCCAGTTCCTGAGGAAACGACAGTTCAAGAAGGGTTGGGAAGAAGGCTGTC
CTCGTTTAAACAACTAGAATTACACGGCGATCTTGCCGCCCTTCTTGGCCTTAATGA
GAATCTCGCGGATCTTGCGGGCGTCCAACTTGCCGGTCAGTCCTTTAGGCACCTCGT
CCACGAACACAACACCACCGCGCAGCTTCTTGGCGGTTGTAACCTGGCTGGCCACAT
AGTCCACGATCTCCTTCTCGGTCATGGTTTTACCGTGTTCCAGCACGACGACTGCGG
CGGGCAGCTCGCCGGCATCGTCGTCGGGCAGGCCGGCGACCCCGGCGTCGAAGATG
TTGGGGTGTTGCAGCAGGATGCTCTCCAGTTCGGCTGGGGCTACCTGGTAGCCCTTG
TATTTGATCAGGCTCTTCAGCCGGTCCACGATGAAGAAGTGCTCGTCCTCGTCCCAG
TAGGCGATGTCGCCGCTGTGCAGCCAGCCGTCCTTGTCGATGAGAGCGTTTGTAGCC
TCGGGGTTGTTAACGTAGCCGCTCATGATCATGGGGCCACGGGACGCACAGCTCGC
CGCGCTGGTTCACACCCAGTGTCTTACCGGTGTCCAAGTCCACCACCTTAGCCTCGA
AAGAAGGCACCACCCTTGCCTACTGCGCCAGGGCTTTGTCGTCCCCTTTCGGGGGGT
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GATCAGTTGGCGCTGATTGTTTTCTGTCAAGAGGTAGCCTGCCGATGCCTGGTAGGT
TGGAGCGTTGCCACCGGTCTCACCCTTAACCTC-3’
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Sequence Alignments for Bisulfite Sequencing of CpG Island 56
Experimental methods, data processing, and NCBI BLAST alignments were performed by
Heather White (2016).

Bisulfite-Converted Control (Zymo, #D5024) Forward Sequence Alignment

Bisulfite-Converted Control (Zymo, #D5024) Reverse Sequence Alignment
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Unconverted HepG2 Mock-Treated Region 6 Forward Sequence Alignment
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Abstract
Teratogens are compounds that can induce birth defects upon exposure of the developing fetus.
To date, most teratogen studies utilize pregnant rodents to determine compound teratogenicity in
vivo.

However, this is a low throughput approach that cannot easily meet the need for

comprehensive high-volume teratogen assessment, a goal of the US Environmental Protection
Agency. In addition, rodent and human development differ substantially, and therefore the use
of assays using relevant human cells has utility. For these reasons, interest has recently focused
on the use of human embryonic stem cells for teratogen assessment. Here we present a highly
standardized and quantitative system for the detection and analysis of teratogens that utilizes
well-characterized and purified highly pluripotent stem cells. We have devised strategies to
mass-produce thousands of uniformly sized spheroids of human ESCs (hESCs) that can be
caused to undergo synchronous differentiation to yield embryoid bodies (EBs) in the presence
and absence of suspected teratogens. The system uses all human cells and rigorously controlled
and standardized EB culture conditions. Furthermore, the approach has been made quantitative
by using high-content imaging approaches. Our system offers distinct advantages over earlier
EB systems that rely heavily on the use on mouse ESCs and EB aggregates of stochastic sizes.
Together, our results show that thousands of suspected teratogens could be assessed using human
EB-based approaches.

Key words
Teratology; Embryoid Bodies; Embryonic Stem Cells.
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Introduction
Annually, 3 to 5% live births in the United States are impacted by birth defects leading to
over 100,000 occurrences of birth defects per year [1, 2]. Teratogens include environmental
compounds to which women are exposed before or during pregnancy through food, drinking
water, airborne sources, and through dermatological exposure.

In addition, many

pharmaceuticals have teratogenic activities. The U.S. Environmental Protection Agency has a
long-standing mission to identify potentially toxic compounds through the Toxcast program
which aims to assess thousands of chemicals of potential concern [3]. However, methods to
screen vast collections of compounds for teratogenicity are currently laborious and plagued by
relatively low throughput, though recent computational approaches have identified a subset of
ToxCast compounds, many with potentially teratogenic effects [4].

Teratogens are compounds that cause birth defects, and these can be either pharmaceutical
agents to which conceptuses are exposed in utero, or environmental compounds. Thalidomide is
a sedative used widely form 1957 to 1961 during pregnancy, and over 10,000 infants were born
with birth defects after thalidomide exposure in utero [5-8]. These unfortunate individuals
presented with limb abnormalities and neural tube closure defects [7]. Sodium valproate is a
widely prescribed anti-epileptic and mood stabilizing agent which is also a histone deacetylase
inhibitor and known teratogen [9-13]. Though women who may potentially become pregnant are
advised to avoid valproate, unintentional exposure may occur during the first days of pregnancy
at the zygote, morula, blastocyst, and gastrulation stages prior to detection of pregnancy.

Pharmaceuticals and xenobiotic compounds have been traditionally tested for teratogenicity
in pregnant animal models and rodent embryo culture [14], and human cell culture models for
teratogenicity are not well developed at present. However, recent innovative approaches include
the use of embryonic stem cells to monitor metabolomic changes in response to toxicants [15],
and assessments of teratogenic effects in zebrafish, where embryonic development can be
monitored by virtue of a transparent fish body plan [16].
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Traditional animal assays for teratogens are excellent (since the readout is based on direct
teratological impacts on developing embryos), but practical difficulties exist with these
approaches. The first impediment is that animal teratological assays are very low throughput. In
addition, there is concern that species-specific differences between rodent and human prenatal
development impact the interpretation of suspected teratogens.

Furthermore, in mammals

(including both rodents and humans), both male and female germ line development occurs
during embryonic development. For this reason, when dosing a pregnant rodent, the mother, the
developing embryo, and the developing embryonic gonadal primordia are simultaneously dosed.
Thus, it is not immediately apparent whether the effects of a compound act directly upon the
mother, the fetus, or the offspring of the exposed fetus, thus creating a conundrum that requires
the assessment of at least 2 generations of offspring for birth defects.
For the reasons above, recent interest has focused on the development of cell culture-based
systems to detect teratogens. ESCs can be cultured indefinitely and coaxed to differentiate in
vitro into a multitude of terminally-differentiated cell types, thus making them an attractive
choice for use in teratology assays. Initial attempts with ESCs relied upon direct exposure of
undifferentiated mouse ESCs to potential teratogens followed by assays of differentiation. More
recently, approaches have been developed that use ESC aggregates to initiate the formation of
embryoid bodies (EBs). Standard methods for producing EBs involve partially disaggregating
mouse or human ESC colonies to yield agglomerates of dozens to hundreds of cells, and these
aggregates are cultured in media that lack signalling molecules that preserve the pluripotent state
(i.e. LIF in the case of mouse ESCs and basic FGF (b-FGF) in the case of human ESCs). Under
these conditions, EBs grow and spontaneously differentiate into cellular lineages that contain
cells of ectodermal, endodermal, and mesodermal identities [17-21]. Together, these and many
other studies show that differentiating EBs come to contain a great many cell types derived from
all three of the major germ layers, and that the accumulation of these cells can be monitored by
cell biological assays. Furthermore, developing EBs exhibit the induction of a wide array of
germ layer-specific gene expression patterns.

However, monitoring complex alterations of

cellular content and gene expression in EBs developing in the presence of compounds is labor
intensive, and EB approaches using uncontrolled aggregation yield EBs of random size and
shape, making the assessment of EB growth difficult to quantitate and of low throughput. We
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aimed to improve the throughput of initial EB teratogen screens by developing standardized
systems to produce uniformly sized EBs combined with synchronous differentiation.

Here we present a standardized human EB system for the detection and modeling of
teratogen action. Our goals were to develop a highly standardized system, with uniformly-sized
human EBs assembled from pristinely pluripotent and quality-controlled hESC cultures. Our aim
was to improve the quality and accuracy of a human EB system for the detection of teratogens
that could be easily adapted to automated high content imaging solutions, with improved
throughput so that in the near future, hundreds to thousands of compounds can be expediently
assessed for teratological risk.
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Materials And Methods
Cell culture
H9 hESCs were obtained from WiCell and cultured on hESC-qualified Matrigel (Corning
#354277). For all assays, we utilized a highly characterized lot of H9 hESCs curated in the
Rasmussen Laboratory established from an initial freeze at passage 19. Media was changed
every day with mTeSR1 (Stem Cell technologies #05857) and mechanically passaged every 4-6
days. Embryoid bodies were formed and maintained in EB Aggrewell medium (Stem Cell
Technologies #05893). Fibroblast cell lines IMR-90 and IMR-91 (Coriell, #I90-83 and #I91S04) were grown at 37C with 5% CO2 on 0.1% gelatin-coated cell culture-treated plates under
aseptic conditions. Culture media consisted of 4.5 g/L glucose DMEM (Invitrogen, #10938025)
supplemented with 10% FBS (Atlanta Biologicals, #S10250H) and 100X Glutamax (Invitrogen,
#35050061).

Cytotoxicity Assays
IMR-90 (I90-83) and IMR-91 (I91S-04) cells were plated on day zero at passages 10 and 14,
respectively. Fibroblasts were treated in quadruplicate with 0 mM, 0.1 mM, 1 mM, 10 mM, 100
mM, and 1 M concentrations of VPA, caffeine, and penicillin G dissolved in culture media on
day 2. On day 3, cells were measured for viability using an MTS assay (Promega, #G3580) in a
SpectraMax Paradigm plate reader from Molecular Devices.

Flow Cytometry
H9 hESCs were incubated with Accutase (Invitrogen, #A11105-01) for 5 minutes or until partial
detachment and passed through a 40 μm cell strainer. Single cells were then pelleted and
resuspended with fresh 4% paraformaldehyde (PFA). After 10 minutes of incubation at room
temperature, cells were exposed to methanol for 15 minutes on ice. Following cell fixation and
permeabilization, the cells were incubated with primary antibodies for 30 minutes on ice using
Stain buffer (BD Biosciences, #554657): Mouse

α-human Tra1-60-FITC (BD Biosciences,

#560380), Mouse α-human SSEA4 PE (BD Biosciences, #560128), Mouse α-human Oct3/4
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AlexaFluor 647 (BD Biosciences, #560329), Mouse α-human Nanog-PerCP-Cy5.5 (BD
Biosciences, #562259).
10,000 events were collected using FACS Calibur instrument (BD Biosciences) after
compensation using CompBeads plus (BD Biosciences, #560497). All data were analyzed using
FlowJo software.

Live cell staining
Live stains of H9 colonies were performed using StainAlive α-SSEA-4 antibody (DyLight 550)
(Stemgent, #09-0097). Briefly, fresh mTeSR1 media containing 10 μg of StainAlive α-SSEA-4
antibody was applied to cultures and incubated 30 minutes at 37C. After two washes with fresh
warm mTeSR1 media, hESC cultures were analyzed on an inverted fluorescence microscope.

Magnetic immunoselection of pluripotent cells
Magnetic purification was conducted using a TRA-1-60 selection kit (Miltenyi Biotec, #130100-832) following manufacturer’s instructions. Briefly, H9 cells at the day of harvest were
incubated with Accutase (Invitrogen, #A11105-01) for 5 minutes or until partial detachment,
passed through a 40 μm cell strainer and resuspended into fresh medium. 2x106 single cells were
then incubated for 5 minutes at 4C with anti-TRA-1-60 MicroBeads with ROCK inhibitor. Cellbead conjugates were then collected on magnetic columns under magnetic field and TRA-1-60
positive cells were collected using 1 ml of culture medium.

Embryoid body formation
Single cell suspensions of TRA-1-60 positive cells were deposited into AggreWell plates (Stem
Cell Technologies) and allowed to aggregate into spheroids. Briefly, 1x106 cells positive for
TRA-1-60 were suspended in 5 ml of EB Aggrewell medium (Stem Cell technologies #05893)
and added into a well of an AggreWell400Ex plate (Stem Cell Technologies, # 27840)
containing approximately 4,700 microwells with a diameter of 400 μm and pretreated with
AggreWell rinsing solution (Stem Cell Technologies, # 07010). AggreWell plates were
centrifuged at 100 x g for 3 minutes to deposit the cells in the microwells and incubated at 37C
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for 24 hours, during which time spherical aggregates of deposited pluripotent cells (spheroids)
were formed.

qEB assay
Spheroid aggregates were collected by firmly pipetting in the AggreWell plates and EB cultures
were initiated by depositing spheroids into low-adherence culture plates treated with either
DMSO (vehicle only), Valproic acid (VPA) (Sigma-Aldrich, #P4543-10G; 1mM), caffeine
(Sigma-Aldrich, #C0750-5G; 0.26mM) or penicillin G (Sigma-Aldrich, #P3032-1MU; 2.8mM).

Gene expression analysis
RNA was extracted using the RNeasy Mini kit (Qiagen, # 74104) according to manufacturer
instructions. 1g of RNA was further converted into complementary DNA using iScript cDNA
Synthesis Kit (Bio-Rad, #1708890). PCR reactions were performed using GoTaq green master
mix (Promega. #M7112) and loaded on a 1% agarose gel.
Primer sequences are:
Nestin_F: 5’-GAAGGGCAATCACAACAGGT-3’
Nestin_R: 5’-GGGGCCACATCATCTTCCA-3’
B-III tub F: 5’-GGCCAAGGGTCACTACACG-3’
B-III tub R: 5’-GCAGTCGCAGTTTTCACACTC-3’
NEFH F: 5’-GTGAAGAGTGTCGGATTGGCT-3’
NEFH R: 5’-ACACAGAGGGAATTTTGGGGA-3’
Brach_F: 5’-TATGAGCCTCGAATCCACATAGT-3’
Brach_R: 5’-CCTCGTTCTGATAAGCAGTCAC-3’
Myf5 F: 5’-CTGCCAGTTCTCACCTTCTGA-3’
Myf5 R: 5’-AACTCGTCCCCAAATTCACCC-3’
c-actin F: 5’-GTACCCTGGTATTGCTGATCG-3’
c-actin R: 5’-CCTCATCGTACTCTTGCTTGCT-3’
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Results
Purification and assessment of highly pluripotent human embryonic
stem cells
We aimed to develop a cell culture system that can detect teratological impacts on human
embryonic cells so we chose to use hESCs as they can be coaxed to differentiate into a wide
variety of endodermal, ectodermal, and mesodermal differentiated cell types. However, working
with pluripotent cells can be challenging since hESCs can undergo undesired alterations during
cell culture that can reduce their pluripotency [20, 22].

Thus we devised a battery of

pluripotency assays based on both pluripotency markers and functional assessments of
pluripotency so that hESC cultures of validated quality could be used. We also developed
strategies to purify highly pluripotent cells from initial hESC cultures for subsequent use in
teratology assays.

We first assessed cultures of hESCs for 4 key markers of pluripotency. These consisted of
two cell surface markers (TRA-60 and SSEA4) and two nuclear markers (OCT4 and NANOG)
which were chosen because they are master regulatory transcription factors necessary for the
maintenance of the pluripotent state in hESCs and induced pluripotent stem cells human
(hiPSCs).

Though we routinely stain such cells for these markers by immunofluorescence, we

wished to quantitatively assess these markers using flow cytometry to more rigorously assess the
expression of pluripotency-associated markers in our starter cell cultures (Fig 1A). To achieve
this goal, we dissociated cultures to single cells, fixed, and permeablized the cells so that nuclear
the nuclear markers (OCT4 and NANOG) are accessible to antibodies, while preserving the
surface markers TRA1-60 and SSEA4. We found that human hESC line H9 (WA09) is strongly
positive for all 4 markers as compared to control cells stained with non-specific IgG. As
expected, undifferentiated H9 cells were positive for TRA1-60 (>95%), SSEA4 (>75%),
NANOG (>95%) and OCT4 (>95%) when compared to IgG stained control cells (Fig 1A). To
functionally investigate the suitability of these markers, H9 cells were differentiated by removing
basic FGF for 9 days, after which only few cells remained positive for TRA1-60 (<10%),
134

NANOG (<5%) and OCT4 (<10%) (Fig 1A). However, we found that SSEA4 is a less robust
marker of pluripotency since after 9 days of differentiation about 50% of cells retained SSEA4
expression. We also performed two channel flow cytometry on undifferentiated H9 cells and
found that 96% of H9 cells were doubly positive for pluripotency markers TRA1-60 and OCT4
(Fig 1B). We also quantitated the decreases in pluripotency marker expression caused by
removal of basic FGF from the medium for 9 days.

All markers declined robustly upon

differentiation, except SSEA4, whose expression was the slowest to respond to removal of basic
FGF (Fig 1C). These studies revealed that TRA1-60 is a superior surface marker of pluripotency
as compared to SSEA4, and that both nuclear transcription factors (NANOG and OCT4) were
expressed only in the undifferentiated cells.

To further assess the behaviour of SSEA4 in pluripotent cell cultures, we noticed that larger
hESC colonies at passage >50 exhibit two patterns of SSEA4 marker expression (S1A Fig).
Using immunofluorescence, we found that cells at colony peripheries were highly positive for
SSEA4, while cells more central to the colony have lower levels of SSEA4. We then
microdissected colonies to isolate peripheral cells (SSEA4 HIGH) and central cells (SSEA4
LOW) and initiated new colonies from the two microdissected subpopulations. In both cases,
colonies arose that still exhibited SSEA4 HIGH cells on their peripheries, suggesting an intrinsic
regulation of SSEA4 expression that is a function of the position of cells within hESC colonies
(S1B Fig). To further investigate this observation, we performed flow cytometry on higher
passage cells and found two peaks (S1C Fig), corresponding to SSEA4 HIGH and SSEA4 LOW
cells. To further investigate molecular differences between both populations, we isolated SSEA4
HIGH and SSEA4 Low cells using magnetic beads cell purification to positively select for
SSEA4 expression cells (S1D Fig). We isolated total RNA from SSEA4 HIGH and LOW cells
and performed semi-quantitative reverse transcriptase PCR (RT-PCR) and found that both
SSEA4 HIGH and LOW cells still exhibited similar expression levels of OCT4, NANOG,
REX1, and hTERT (S1C Fig). We also made standard (random sized) EBs from SSEA4 LOW
and HIGH cells, and found that EBs derived form both cell populations robustly expressed
mesodermal or ectodermal genes after 17 days of EB differentiation (S1D Fig). We conclude
that TRA1-60 is a superior cell surface marker of pluripotency as compared to SSEA4. In
addition to the above, we wished to perform functional tests of pluripotency by differentiating
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cells to ectoderm, endoderm, and mesoderm lineages. We used a kit containing supplements and
growth factors allowing the directed differentiation into the three germinal layers in 4 days and
the staining of SOX17 (endoderm), OTX2 (ectoderm) and BRACHYURY (mesoderm) (RnD
Systems; cat. no. SC027). We found that early passage H9 cells can readily form cells of all
three germ layers by this functional test (data not shown).

Development a standardized and quantitative human EB cell
culture system suitable for high-content imaging
hESCs and EBs derived from them have been used as cell culture models to assess
toxicological responses to exogenous compounds, but most of these studies have used mouse ES
cells and EBs of random size and shape. Though these past approaches have been useful, we
wished to develop a highly standardized and quantitative method to detect and analyze
teratogens that could be adapted to high-content imaging strategies using mass-produced human
EBs of uniform size and shape. One design consideration for us was to insure that only the very
best (most highly pluripotent) cells are used to form EBs. We therefore made use of our findings
outlined in the section above, and utilized early passage (passage 19) H9 hESCs for this purpose.
Furthermore, we found it prudent to dissociate hESC colonies to single cells using accutasemediated disaggregation to single cells followed by purification of TRA1-60 positive cells by
magnetic bead selection (Fig 2A), so that we could be sure that only highly purified populations
of hESCs would be used for the initiation of EB cultures.

Though we used only highly

pluripotent low passage H9 hESCs, we decided to routinely purify TRA1-60 positive cells by
this method to initiate all subsequent EB cultures.

This strategy insures that starting cell

populations used to initiate EB formation are devoid of any contaminating differentiated cells,
and this approach also provides a good measure of quality control of the cells used to initiate EB
culture.

We also wished to mass-produce EBs of initial uniform size to make the EB cultures
uniform and synchronous in their growth and differentiation. To achieve this goal, we plated
disaggregated and TRA1-60 positive (magnetically purified) cells into Aggrewell plates (Stem

136

Cell Technologies) at an initial seeding density of 2x105 cells per ml in EB culture medium
(Stem Cell Technologies).

The pyramidal wells of Aggrewell plates are hydrophobic and

prevent cellular adhesion to the substratum. We found that after 3 days of aggregation under
these conditions, we could produce about 4000 spherical aggregates (spheroids) of hESCs, which
were used to initiate EB culture. (Fig 2B). Using these approaches, we were able to produce
thousands of uniformly sized human EBs from cultures of hESC line H9 using starting cell
populations that are highly uniform and pluripotent, as the cells were positively purified using
magnetic beads that bind TRA1-60+ pluripotent cells (Fig 3). Once we developed the capability
to mass-produce uniform spheroids, we wished to explore alternative means of EB culture and
quantification to render the system more versatile of teratogen testing. Uniformly sized and
spherical day 0 EBs (spheroids) were harvested from Aggrewell plates, and further cultured in
three different ways: First, we deposited individual day 0 EBs into individual wells of low
adherence multi-well plates containing differentiation medium using a 200 μl-tip cut at the
extremity. The individually plated EBs were allowed to grow and differentiate for an additional
12 days, and since single EBs were deposited into each well, we could monitor the growth and
behavior of individual EBs as a function of time. Secondly, we plated pools consisting of
hundreds of uniform day 0 spheroids into low adherence 6 cm dishes and allowed them to
differentiate for 12 days. This strategy allowed us to monitor EB growth on populations of EBs
so that statistically rigorous assessments of mean EB size (growth) could be obtained. Lastly, we
plated EBs into Matrigel-coated wells. This strategy allows EBs to adhere to the cell culture
substrate, which allows cells to proliferate and grow outward from the core of attached EBs.
These combined approaches allowed us to quantitatively assess the growth of EBs under 3
conditions, using cell culture strategies that could easily be adapted for high-content image
analysis.

Performance of the quantitative human EB model with selected
teratogens
To assess the sensitivity and accuracy of our EB system (hereafter called the human
quantitative embryoid body teratology model system, hqEB system, outlined in Fig. 2) we chose
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to use three compounds known to have teratogenic activities. We chose to study caffeine (a
weak teratogen), penicillin-G (a moderate teratogen), and Valproic acid (VPA, highly
teratogenic). Caffeine has been studied in the context of embryonic development and was
reported to impair normal chick neurodevelopment especially affecting eye formation [23, 24].
Treatment of pluripotent stem cells with caffeine also dysregulates the transcription of important
early differentiation genes [19]. Penicillin-G was implicated in kidney development defects in
the rat and has been widely studied for its developmental neurotoxicity [25, 26]. Neural
teratogenicity has been observed after treatment of human embryonic stem cells with VPA [27].
VPA exposure during pregnancy can cause ear malformation [28]. Our goal was to determine if
the hqEB system can robustly and quantitatively assess teratogenicity based on the potential
effects of these reference teratogens in our newly developed system.

Determination of caffeine, penicillin-G and valproic acid subcytotoxic concentrations and teratogen assay dosing
In principle, EB growth kinetics could be affected by either simple cellular cytotoxicity, or
due to teratogenic effects that alter cellular proliferation and differentiation. Since we were more
interested in teratogenicity as opposed to overt cytotoxicity, we performed dose-response
cytotoxicity assays to determine the LC50 for each of the three compounds. We first determined
by dose response the cytotoxicity of the drugs at five concentrations in two human fibroblast cell
lines: I90-83 (also called IMR-90) and I91S-04 (also called IMR-91) (Fig S2A). The results
indicated that both fibroblast cell lines had similar LC50 values upon exposure to each teratogen.
This dosing data allowed us to choose teratogen concentrations for use in the hqEB system that
do not elicit overt cytotoxic effects. The concentrations chosen for hqEB analyses in this study
were 0.26 mM, 2.8 mM and 1 mM for caffeine, penicillin-G and VPA respectively. These
concentrations are 10-fold or more below the LC50 for each compound. To further control for
potential cytotoxicity of the compounds at these concentrations, we treated hESC H9 cells for 72
hours at these sub-cytotoxic concentrations. We found no significant impact on hESC cell
colony growth or morphology after 72 hours of treatment (S2B Fig).
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Individual EB monitoring
We first investigated the use of individually cultured, non-adherent EBs exposed to the
reference teratogens. First, we prepared hESC spheroids using Aggrewell plates as described
above, using magnetically purified TRA1-60+ cells to initiate spheroid formation. After 3 days
of aggregation (hereafter designated as day 0), spheroids of uniform size and shape were
deposited individually into single wells of low adherence 24-well plates, the media was changed
from mTeSR1 to EB differentiation medium, and 3 reference teratogens were added at the
established sub-cytotoxic concentrations. Four individual EBs were grown in the presence of
each teratogen (quadruplicate). We analyzed the growth and shape of individual EBs by
microscopy every 3 days for a total of 12 days in differentiation medium. (Fig 4A). Control EBs
that were not treated with teratogens exhibited consistent growth over the course of the
experiment. In contrast, exposure to VPA greatly curtailed the growth of EBs. After only 3 days
of teratogen exposure, we observed that the growth of VPA-treated EBs was arrested, and this
failure to grow persisted throughout the course of the experiment (Fig 4A,B). In the case of
caffeine (weakly teratogenic), we observed a modest but detectable effect on EB growth, which
became apparent and statistically significant at days 9 and 12.

The effect of penicillin-G

(moderately teratogenic) was stronger than that of caffeine, but less severe than VPA. EBs
treated with Penicillin-G failed to increase significantly in size after 6 days of treatment (Fig
4A,B). We used microscopy imaging software to quantitatively assess impacts on the shape of
EBs. To do this, we calculated the circularity coefficient for each time point (expressed as
circularity = 4(area/perimeter2)). This measure showed that shape alterations can also be
detected in the hqEB system. We found subtle effects on EB circularity using this approach in
the case of caffeine (Fig 4C). Together these results show that teratogenic effects can be readily
detected by the hqEB system. We note that these findings suggest that the hqEB system could
easily be adapted to utilize automated high-content imaging solutions in future larger scale
applications.

Additional analyses of teratogen-exposed EBs
In addition to individual EB monitoring, we wanted to see if similar results could be obtained
by analyzing pools of EBs exposed to teratogens. To do this, dishes containing at least 100
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unattached EBs of the same size were treated with the three compounds for 12 days and analyzed
by microscopy every three days (Fig 5A). The diameters and growth kinetics of EBs were
consistent with the previous assay, and VPA teratogenicity was again detected after only three
days of teratogen exposure, while EBs treated with Penicillin-G stopped growth by 9 days after
aggregation (Fig 5B). Using this approach, caffeine treatment exhibited little or no effect on EB
growth (Fig 5B). EBs were then analyzed by qRT-PCR for induction of selected germ layer gene
expression (Fig 5C). We found that mesoderm and ectoderm genes were induced and robustly
expressed by day 12. We found that caffeine treatment had no major effects on expression of
these genes, while penicillin-G treatment had some effect on expression of these genes. Lastly,
we wished to see if we could track compound teratogenicity in culture conditions in which
spheroids are allowed to attach to the culture substratum. We therefore aggregated H9 hESCs for
3 days and plated the spheroids onto Matrigel-coated plates concurrently with change to
differentiation medium. As expected, we noted outgrowths of differentiated cells the spread out
from the centers originally formed at the sites of EB attachment. The outgrowths were irregular
in shape, and after 72 h of treatment with the three compounds, no phenotypic differences were
observed (Fig 5D). Our results indicate that monitoring individual EBs grown under nonadherent conditions constituted an approach that robustly and quantitatively detected teratogenic
effects. In contrast, we found the adherent EB strategy less useful, because outgrowth area and
shape are more variable.
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Discussion
We developed and refined a human EB system that utilizes highly characterized cells of
demonstrated pluripotency in such a way that the effects of teratogens can be evaluated and
quantitated by numerical descriptors with statistical accuracy.

Since teratogens impact the

course of directed cellular differentiation during embryogenesis, we strived for utilizing only the
very highest quality of cells to initiate EB cultures. To this end, we assessed hESCs rigorously
for their pluripotency-associated marker expression. We found that TRA1-60 is a superior
surface pluripotency marker as compared to SSEA4. Furthermore, we wished to initiate our EB
cultures with spherical aggregates of hESCs, which we found could be mass-produced in
aggrewell plates. To do this, we faced a challenge in that suspensions of single cells are required
in order to seed aggrewell plates.

This is complicated by the fact that cell-cell contacts

(mediated by E-Cadherins in hESCs) are required to maintain the pluripotent state of hESCS.
We therefore developed a strategy whereby feeder cell-free starter cultures of hESCs are
disaggregated to single cells by Accutase treatment. The singularized cells were maintained in
the presence of ROCK inhibitor, which can stabilize the maintenance of pluripotency of single
hESCs during the disaggregation of hESC colonies to single cells. We also immunologically
purified TRA1-60+ cells using magnetic beads and used these to seed aggrewell plates to prepare
large numbers of uniform spheroids that could in turn be used to initiate EB cultures. We found
that we can prepare large numbers of EBs by this method, which are of initial uniform size, and
whose growth and proliferation occur synchronously. We found that by simply monitoring a
cohort of EBs treated with teratogens (at doses that are sub-cytotoxic), that we could observe
defects in EB growth characteristics that could be quantified precisely.

We were able to

reproducibly and quantitatively detect effects on EB development using a panel of three
reference teratogens. This report builds on previous successes with human EBs, but our system
makes use of highly standardized EBs of known pluripotency which are of standardized and
uniform size and pluripotency prior to differentiation in the presence of potentially teratogenic
compounds.
The hqEB system has features that make it attractive for future assessments of teratogen
action. First, our system utilizes relevant human cells of embryonic cellular identity ( hESCs),
which model the inner cell mass of blastocyst-stage preimplantation embryos. Furthermore, EBs
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differentiate in vivo to form primitive cells of ectodermal, endodermal, and mesodermal
lineages. Also, hESCs and EBs derived from them contain intact complete genomes, and offer
obvious advantages as compared to immortalized cell lines. We also initiated our EBs with
known numbers using TRA1-60+ immunopurified hESC starter cells and found that EB growth
(and the impacts of teratogen exposure) can be monitored continuously and assessed
quantitatively. The hqEB system is of much higher throughput than costly animal experiments.
Though these are useful features, the EB system also has limitations. Firstly, metabolites of
parent compounds may be responsible for teratogenicity in vivo, and the EB system presented
here utilizes relevant embryonic cells (the targets of teratogens) but these cell types cannot
metabolize parent compounds. Thus the hqEB system is at present not suited to the assessment of
unknown metabolites of parent compounds. In addition, EB systems in general contain early
embryonic cells, and therefore later developmental effects cannot easily be modeled with such
cells. Therefore, future uses of the hqEB system and its future iterations should be of good use,
but it is unlikely that its use will fully supplant the use of animals studies, which could better
detect subtle and late-term impacts on embryo health (though with the caveat that rodent
embryonic development is clearly not the same as human embryonic development).
In the future, it should be relatively straight forward to adapt the hqEB system to automated
high content imaging, since individual EBs can be cultured individually in multi-well plates and
assessed periodically by automated cell culture microscopy approaches and associated image
acquisition and analysis software. We also note that our uniform EBs could also be cultured in
multiplexed microfluidics devices in which continuous perfusion and compound dosing can be
performed. It is also noteworthy that complex mixtures (including drinking water samples)
could readily be assessed by these approaches. For these reasons, we suspect that improved
human EB methods such as those described here will gain added importance in future large scale
assays of teratogens. Furthermore, the system would be useful during safety assessment stages
of development of new pharmaceuticals. The approaches described in this study should allow
the assessment of hundreds of potential teratogens since the assay is based on morphological
assays of EBs that are initially uniform, develop synchronously, and that can be assessed at
intervals over the course of differentiation. Furthermore, our approaches are readily adaptable to
microfluidics and high-content imaging.

Once prospective teratogens are identified by these

expedient means, it should then be possible to perform more rigorous studies of teratogenic
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mechanisms by investigating the impacts of compounds on the cellular composition of impacted
EBs (including their relative content and identities of cells of ectodermal, endodermal, and
mesodermal origin) as well as detailed analyses of altered gene and protein expression, which
collectively, should shed light on specific developmental pathways impacted by specific
teratogens.
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Fig 1. Simultaneous detection of four pluripotency markers by flow cytometry. (A) Flow
cytometric analysis of permeablized H9 hESCs. Cells were exposed to antibodies against
TRA1-60, SSEA4, NANOG and OCT4. IgG antibody was used as negative control. Top:
Cytometry profiles of undifferentiated H9 cells. Bottom: Cytometry histograms of H9 cells
9 days after removal of bFGF. (B) Flow cytometric analysis of undifferentiated H9 cells for
the co-stained for TRA1-60 and OCT4. (C) Quantification of positive cells for TRA1-60,
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SSEA4, NANOG and OCT4 in comparison to IgG control for both undifferentiated and
differentiated H9 cells.

Fig 2. Outline of human quantitative embryoid body (hqEB) system strategies. (A)
Preparation of spheroids from TRA1-60+ magnetically purified hESCs. Low passage H9
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cells were dissociated to single cells by Accutase treatment, then TRA1-60+ cells were
magnetically purified. These were then plated at known density into Aggrewell plates to
from spheroids of uniform size. (B) Alternative plating and differentiation approaches.
Three methods were assessed: (1) Spheroids were deposited individually into cell culture
plate wells, and imaged every 3 days. (2). Pools of EBs are plated into 6 well dishes under
non-adherent conditions, imaged, quantitated for size. (3) Spheroids are attached onto
Matrigel coated plates and allowed to proliferate and spread under adherent conditions.
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Fig 3. Representative images of hESC spheroids prepared from TRA1-60+ purified cells.
Spheroids containing uniform numbers of cells were prepared in Aggrewell plates using
TRA1-60+ cells. (A) Aggrewell plate containing spheroids aggregated for 3 days (1.25X
magnification). (B) Aggrewell plate containing spheroids aggregated for 3 days (4X
magnification). (C) Aggrewell plate containing spheroids aggregated for 3 days (10 X
magnification). (D) Spheroids imaged immediately after aggregation.
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Fig 4. Consequences of teratogen exposure on individually cultured EBs. (A) H9 hESCs
were dissociated with Accutase, formed into spheroids, and plated into individual wells
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under non-adherent conditions (day 0). Media was changed to EB differentiation medium
and individual EBs were imaged microscopically every 3 days for a total of 12 days of
differentiation. Individual EBs were treated with vehicle only (DMSO), Caffeine,
Penicillin-G, and Valproic acid and images were acquired after 0, 3, 6, 9, and 12 days of
differentiation. (B) EBs were quantitated by measuring the apparent size (μm2) of
individual embryoid bodies after treatment with DMSO, Caffeine, Penicillin-G or Valproic
acid. Results shown indicate the means and standard deviations by quantitatively imaging a
cohort of 3 independently cultured EBs each tested with each of the 3 compounds.
(*P<0.05; **P<0.01; ***P<0.001 as compared to DMSO). (C) Shape quantification
expressed by the circularity coefficient of individual EBs treated with DMSO, Caffeine,
Penicillin-G or Valproic acid. Results shown indicate the means and standard deviations
obtained by quantitatively imaging a cohort of 3 independently cultured EBs each tested
with each of the 3 compounds.
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Fig 5. Monitoring EB growth in pooled populations of EBs grown under non-adherent
conditions. (A) Representative images of EBs grown in the presence of DMSO (vehicle
only), Caffeine, Penicillin-G and Valproic acid. (B) Size quantification of EB populations
treated with DMSO, Caffeine, Penicillin-G or Valproic acid. Results are the means +/standard deviation. (n = 17 to 69 independent EBs after 3, 6, and 9 days of culture in the
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presence of teratogens (*P<0.05; **P<0.01; ***P<0.001 as compared to DMSO). (C)
Analysis of mRNA expression of differentiation markers from EBs treated with DMSO,
Caffeine or Penicillin-G over the course of 12 days of EB differentiation. RT-PCR
performed to detect mesodermal (KDR, C-ACTIN and BRACHYURY) and ectodermal
mRNAs (NETO2, NCAM, NES, BIII-TUB and NEFH). GAPDH is used as loading
control. (D) EB spreading assay performed on attached EBs cultured on Matrigel (0 hours)
and treated with DMSO, Caffeine, Penicillin-G or Valproic acid for 72 hours in
differentiation medium.
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S1 Fig. Analysis of pluripotency marker expression in hESC line H9. (A) High passage H9
cell colony live stained with α-SSEA4 antibody coupled to PE. i and ii (insets) show colony
regions expressing high (colony peripheries) and low (colony interior) levels of SSEA4
respectively. (B) Microdissection of H9 cell colonies to isolate peripheral cells (SSEA4
HIGH) and central cells (SSEA4 LOW). Bottom: representative colonies initiated with
SSEA4 HIGH and LOW dissected cells after 10 passages. (C) Flow cytometry analysis of
high passage H9 cells for the stem cell marker SSEA4. Note the presence of two
populations of cells expressing different levels of SSEA4 as compared to IgG negative
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control. H9 colonies were dissociated to single cells and incubated with an anti-SSEA4
antibody coupled to magnetic beads. Immunopurified cells express high levels of SSEA4.
(D) Pluripotency marker expression analysis on hESC line H9 sorted for TRA1-60 or
SSEA4 (low and high expression). RT-PCR was used to detect OCT4, NANOG, REX1 and
hTERT mRNAs and GAPDH was used as loading control. To determine if the expression
of SSEA4 status impacts differentiation, H9 EBs were made from hESCs expressing high
or low levels of SSEA4 and then differentiated for 17 days. RT-PCR performed on mRNA
isolated from the EBs and assessed for expression of KDR, C-ACTIN, BRACHYURY
(mesoderm) and NETO2, NCAM, NES, BIII-TUB and NEFH (ectoderm). GAPDH is used
as an internal loading control.
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S2 Fig. Determination of sub-cytotoxic compound doses. (A) Dose-response curves of
teratogens two human fibroblast cell lines (I90-83 and I91S-04) exposed to caffeine,
penicillin-G, and Valproic acid. Red arrow indicates the concentration chosen for the hqEB
system. (n = 3 independent experiments). (B) Representative images of hESC line H9
treated with DMSO or Valproic acid for 24, 48 and 72 hours. Insets show higher
magnification images of cellular morphology within colonies.
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